documents incorporated reference incorporated scheringplough corporation proxy statement th e annual meeting shareholders may part iiitable contents p age part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report internal control financial reporting part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules reports form k signatures exexii savings advantage plan exl retirement benefits equalization plan ex computation ratio earnings fixed charges ex subsidiaries registrant ex consent deloitte touche llp ex independent auditor 's consent ex power attorney ex certification ex certification ex certification ex certificationtable contents part item business overview business scheringplough company refers scheringplough corporation subsidiaries except otherwise indicated context schering corporation predecessor company incorporated new york new jersey trademarks indicated capital letters k property licensed promoted distributed scheringplough corporation subsidiaries related companies scheringplough global sciencebased health care company leading prescription consumer animal health products internal research collaborations business partners scheringplough discovers develops manufactures markets advanced drug therapies meet important medical needs scheringploughs vision earn trust physicians patients customers shareholders serves around world scheringploughs worldwide headquarters kenilworth new jersey website wwwscheringploughcom april board directors named fred hassan new chairman board chief executive officer scheringplough corporation leadership six eightyear action agenda plan directed toward goals stabilizing repairing turning around scheringplough produce longterm value shareholders established new leadership team recruited segment information new management team reorganized business one managed along geographic lines primary segments us restofworld business organized around products currently scheringplough three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent scheringploughs current management reporting structure prescription pharmaceuticals prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products within prescription pharmaceutical segment three customer groups primary care specialty care cholesterol franchise principal products segment include primary care allergy respiratory nasonex oncedaily nasalinhaled steroid nasal allergy symptoms including congestion treatment nasal polyps patients years age older clarinex nonsedating antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist marketed scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduced bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma antibiotics avelox broadspectrum fluoroquinolone antibiotic certain respiratory skin infections cipro broadspectrum fluoroquinolone antibiotic certain respiratory skin urinary tract infections dermatologicals elocon mediumpotency topical steroid cream lotion ointment disorders levitra phosphodiesterase type inhibitor pde comarketed scheringplough united states treatment male erectile dysfunction table contents specialty care antivirals pegintron powder injection pegylated interferon product chronic hepatitis c approved dosing according patient body weight intron injection chronic hepatitis b c antiviral indications rebetol capsules use pegintron intron chronic hepatitis c antiinflammatories remicade antitnf antibody marketed scheringplough outside united states treatment rheumatoid arthritis crohns disease ankylosing spondylitis psoriatic arthritis psoriasis firstline therapy treatment early rheumatoid arthritis oncology temodar capsules certain types brain tumors including newly diagnosed glioblastoma multiforme caelyx longcirculating pegylated liposomal formulation cancer drug doxorubicin marketed scheringplough outside united states treatment certain ovarian cancers kaposis sarcoma metastatic breast cancer intron injection marketed numerous anticancer indications worldwide including adjuvant therapy malignant melanoma acute coronary care integrilin injection platelet receptor gp iib iiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention united states well prevention early myocardial infarction patients acute coronary syndrome countries disorders subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone marketed scheringplough certain countries outside united states treatment opiate addiction cholesterol franchise zetia novel cholesterolabsorption inhibitor discovered scheringplough scientists use combination statin drugs monotherapy lower cholesterol vytorin cholesterollowering tablet combining dual action zetia merck co incs statin zocor consumer health care consumer health care segment develops manufactures markets otc foot care sun care products principal products segment include overthecounter products claritin nondrowsy antihistamines drixoral cold allergy allergy sinus flu nasal decongestant tablets afrin nasal decongestant spray correctol laxative tablets foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils lipprotection products sunless tanning products solarcaine sunburn relief products animal health animal health segment discovers develops manufactures markets animal health products principal products segment include livestock products nuflor bovine swine antibiotic banamine bovine swine antiinflammatory mpac swine pneumonia vaccine poultry products paracox coccivac coccidiosis vaccines poultry table contents companion animal products otomax steroid otitis dogs exspot topical insecticide dogs homeagain pet recovery service zubrin antiinflammatory analgesic dogs aquaculture products slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish net sales segment ye ar en ded decem ber dollars millions prescription pharmaceuticals consumer health care animal health consolidated net sales profit segment ye ar en ded decem ber dollars millions prescription pharmaceuticals consumer health care animal health corporate consolidated profitloss tax corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies item financial statements supplementary data k corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve million representing companys current estimate resolve massachusetts investigation well investigations disclosed awp investigations state litigation disclosed awp litigation note legal environmental regulatory matters item financial statements supplementary data estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs well million asset impairment charges estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs million provision increase litigation reserves million asset impairment charges estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million table contents see note special charges item financial statements supplementary data k additional information global operations nonus operations generate majority companys profits cash flow nonus activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition scheringplough represented markets licensees distribution arrangements currently scheringplough business operations countries approximately employees outside us nonus operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing reimbursement restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact scheringploughs consolidated financial results additional information global operations see item managements discussion analysis financial condition results operations segment information described k net sales geographic area dollars millions united states europe canada pacific area asia latin america consolidated net sales company subsidiaries countries outside us single international country except france japan italy accounted percent consolidated net sales past three years net sales presented geographic area companys customers located consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales llars n millions total international net sales france japan italy net sales customer consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dol lars millions mckesson corporation single customer except mckesson corporation major pharmaceutical health care products distributor accounted percent consolidated net sales past three years table contents longlived assets geographic location dollars millions united states singapore ireland puerto rico total longlived assets shown geographic location primarily property supplemental sales information sales products comprising percent companys us international sales year ended december follows amo unt perce ntage dollars millions us nasonex otc claritin international remicade pegintron scheringplough net sales include sales vytorin zetia marketed partnership merck company accounts joint venture equity method accounting see note equity income cholesterol joint venture item financial statements supplementary data k company disaggregate assets segment basis internal management reporting therefore information presented research development scheringploughs research activities primarily aimed discovering developing new prescription products enhancements existing prescription products medical commercial significance companysponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales percent consolidated net sales approximately percent consolidated net sales scheringploughs research activities concentrated therapeutic areas respiratory diseases inflammatory diseases infectious diseases oncology cardiovascular metabolic diseases central nervous system disorders scheringplough also substantial efforts directed toward biotechnology immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale companys product pipeline lists significant products development available scheringplough website wwwscheringploughcom table contents patents trademarks intellectual property rights overview intellectual property protection critical scheringploughs ability successfully commercialize product innovations scheringplough owns applied licensed rights large number patents us countries relating molecules products product uses formulations manufacturing processes assurance patents scheringplough seeking granted patents scheringplough granted would found valid challenged moreover patents relating particular molecules products uses formulations processes preclude manufacturers employing alternative processes marketing alternative products formulations might successfully compete companys patented products outside us standard intellectual property protection pharmaceuticals varies widely many countries reasonably strong patent laws countries currently provide little effective protection inventions intellectual property rights traderelated aspects intellectual property agreement trips administered world trade organization wto countries agreed provide nondiscriminatory protection pharmaceutical inventions assure adequate effective rights available patent owners possible changes agreement made future diminish delay implementation developing countries soon assess much company impacted commercially changes product patent expires patent holder often loses effective market exclusivity product result rapid sharp material decline sales formerly patented product particularly us however cases innovator company obtain additional commercial benefits manufacturing trade secrets laterexpiring patents processes uses formulations trademark use exclusivity may available pharmaceutical regulatory laws scheringploughs intellectual property portfolio patent protection certain scheringplough molecules products processes uses important scheringploughs business financial results many companys products addition patents compound scheringplough holds patents manufacturing processes formulations uses may extend exclusivity beyond expiration compound patent scheringploughs subsidiaries licensed rights number patents patent applications us abroad patents patent applications relating scheringploughs significant products including without limitation vytorin zetia remicade nasonex intron pegintron temodar clarinex material importance scheringplough worldwide scheringplough sells major products trademarks also material aggregate business financial results trademark protection varies throughout world protection continuing countries long mark used countries long registered registrations normally fixed renewable terms patent challenges hatchwaxman act drug price competition patent term restoration act commonly known hatchwaxman made complex set changes patent new drug approval laws us hatchwaxman drug could approved without providing us food drug administration fda complete safety efficacy studies known complete new drug application nda hatchwaxman authorizes fda approve generic versions innovative medicines without information upon filing abbreviated new drug application anda anda generic manufacturer must demonstrate bioequivalence generic version ndaapproved drug safety efficacy hatchwaxman provides limited patent term restoration partially make patent term lost time ndaapproved drug regulatory review ndaapproved drugs also receive limited period data exclusivity prevents approval anda applications specific time periods approval nda approved drug table contents absent successful patent challenge fda approve anda innovators patents expire however generic manufacturer may file anda seeking approval expiration applicable data exclusivity alleging one patents listed innovators nda invalid infringed allegation commonly known paragraph iv certification innovator must file suit generic manufacturer protect patents one ndalisted patents successfully challenged first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue marketing activities competition prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals certain managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distribution samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers footcare otc suncare products sold wholesale retail drug food chain mass merchandiser outlets promoted directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies significantly larger scheringplough substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used scheringplough products include research development new improved products varied dosage forms strengths switching prescription products nonprescription status us many scheringploughs products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products competing products therapeutic category longer protected patents exclusivity available pharmaceutical regulatory laws scheringplough operates primarily prescription pharmaceutical marketplace however appropriate scheringplough sought may future seek regulatory approval switch prescription products overthecounter otc status means extending products life cycle way otc marketplace another means maximizing return investments discovery development government regulation companys major business segments subject significant regulation multiple jurisdictions section describes general regulatory framework additional information cost regulatory compliance specific impacts companys business financial condition described heading regulatory competitive environment company operates managements discussion analysis later k additional information regulatory matters found item legal matters note consent decree note legal environmental regulatory matters item financial statements supplementary data k prescription drug segment regulations apply phases business including regulatory requirements conduct standards clinical trials example requiring use good clinical practices gcps apply research development stage table contents regulatory requirements conduct standards postapproval clinical trials required regulatory approval begin marketing new drug market existing drug product new indications regulations prescribing manner drugs manufactured packaged labeled advertised marketed distributed regulations impacting pricing drugs regulatory requirements assess report adverse impacts side effects drugs used clinical trials well marketed drugs called pharmacovigilance ability regulatory authorities remove product market recall certain batches products us national regulation phases prescription drug business except pricing centralized food drug administration fda fda responsible protecting us public health assuring safety efficacy security human veterinary drugs biological products medical devices generally free market pricing us although centers medicare medicaid services cms medicare part b include provisions pricing drugs elderly disabled indigent receive federal prescription benefits company also committed complying voluntary best practices pharmaceutical research manufacturers america phrma trade industry group member regarding marketing advertising practices european union eu including companys key markets united kingdom france germany italy regulation local country level additional regulation eu level european medicines agency emea pharmaceutical products regulated levels various national mutual recognition centralized regulatory procedures emea coordinates evaluation supervision medicinal products throughout european union paneu market pricing system however individual member states various systemsagencies regulate price local level japan regulation pharmaceuticals medical device agency pmda pmda regulates pharmaceuticals medical devices development postmarketing use japanese government regulates pricingreimbursement pharmaceutical products japan complicated pricing process includes benchmarks prices western countries united states canada select eu countries major countries influence pricing even cms united states increasing pressure pharmaceutical industry bring products market provide differentiation versus existing products lead expensive scientifically challenging clinical trials order generate type data new products versus marketed comparators information merck scheringplough joint ventures may company merck co inc merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company table contents cholesterol agreements provide company merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approved use us launched several international markets company utilizes equity method accounting joint venture cholesterol agreements provide sharing net incomeloss based upon percentages vary product sales level country us market scheringplough receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough partners share profits equally scheringploughs allocation joint venture income increased milestones earned either partners share joint ventures net incomeloss subject reduction partner fails perform specified minimum number physician details particular country partners agree annually minimum number physician details country partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details set annual basis reimbursed amount equal partners physician details multiplied contractual fixed fee scheringplough reports receipt reimbursement part equity income cholesterol joint venture amount represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directto consumer advertising direct identifiable outofpocket promotion agreedupon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners due virtual nature cholesterol joint venture company incurs substantial costs selling general administrative costs reflected equity income cholesterol joint venture borne overall cost structure company costs reported respective line items statements consolidated operations cholesterol agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either company merck allergyasthma agreements provide joint development marketing partners oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck scheringplough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remains clinical development new phase iii clinical trials planned table contents raw materials raw materials essential scheringplough available adequate quantities number potential suppliers energy expected available scheringplough sufficient quantities meet operating requirements seasonality certain companys products particularly respiratory suncare categories seasonal nature seasonal patterns pronounced effect consolidated operations scheringplough environment date compliance federal state local laws regarding discharge materials environment protection environment material effect scheringploughs capital expenditures earnings competitive position employees approximately people employed scheringplough december available information scheringploughs ks qs ks amendments reports filed sec available free charge scheringploughs website soon reasonably practicable materials electronically filed sec scheringploughs address world wide web wwwscheringploughcom since scheringplough began practice third quarter report available scheringploughs website within hours filing reports filed scheringplough sec may read copied secs public reference room f street ne washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec item risk factors companys future operating results cash flows may differ materially results described k due risks uncertainties related companys business including discussed addition factors represent risks uncertainties could cause actual results differ materially implied forwardlooking statements contained report key company products generate significant amount companys profits cash flows events adversely affect market leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow dependent upon increasing profitability companys cholesterol franchise consisting vytorin zetia addition products clarinex pegintron rebetol remicade temodar otc claritin nasonex accounted material portion revenues result companys dependence key products events adversely affect markets products could significant impact results operations events include loss patent protection increased costs associated manufacturing otc availability companys product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason table contents specifically profitability companys cholesterol franchise may adversely affected introduction generic forms two competing cholesterol products lose patent protection addition generic flonase fluticasone propionate approved may unfavorably impact corticosteroid nasal spray market past examples events recent years adversely affected market leading products include events affected market clarinex pegintron rebetol particularly us clarinex continues experience intense competition prescription us allergy market launch claritin otc competing otc loratadine product us december introduction generic allegra fexofenadine us september addition result introduction competitors product pegylated interferon introduction generic ribavirin value pegintron pegylated interferon rebetol ribavirin combination therapy hepatitis severely diminished earnings cash flow materially negatively impacted high risk funds invested research generate financial returns development novel drugs requires significant expenditures low probability success high rate failure inherent research develop new drugs treat diseases result high risk funds invested research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested companys success dependent development marketing new products uncertainties regulatory approval process may result failure products reach market products appear promising development may fail reach market numerous reasons including following findings ineffectiveness harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others intellectual property protection important contributor companys profitability patents covering companys products expire found invalid generic forms companys products may introduced market may material negative affect results operations intellectual property protection critical scheringploughs ability successfully commercialize products upon expiration successful challenge companys patents covering product competitors may introduce generic versions products may include companys well table contents established products generic competition could result loss significant portion sales downward pressures prices company offers formerly patented products particularly us patents patent applications relating scheringploughs significant products material importance scheringplough additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect companys results operations patent disputes costly prosecute defend adverse judgments could result damage awards increased royalties similar payments decreased sales patent positions highly uncertain patent disputes pharmaceutical industry unusual adverse result patent dispute involving companys patents may lead loss market exclusivity render companys patents invalid adverse result patent dispute involving patents held third party may preclude commercialization companys products force company obtain licenses order continue manufacturing marketing affected products negatively affect sales existing products result injunctive relief payment financial remedies example companys product dr scholls freeze away wart removal product currently subject patent infringement action brought third party company adverse outcome action may result companys inability continue manufacturing product even company ultimately successful particular dispute company may incur substantial costs defending patents intellectual property rights example generic manufacturer may file abbreviated new drug application seeking approval expiration applicable data exclusivity alleging one patents listed innovators new drug application invalid infringed allegation commonly known paragraph iv certification innovator ability file suit generic manufacturer enforce patents recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights us foreign regulations including establishing companys ability price products may negatively affect companys sales profit margins company faces increased pricing pressure us abroad managed care organizations institutions government agencies programs could negatively affect companys sales profit margins example medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january anticipated may result increased purchasing power negotiating behalf medicare recipients addition legislation concerning price controls trends could affect companys business include legislative regulatory action relating pharmaceutical pricing reimbursement health care reform initiatives drug importation legislation involuntary approval medicines otc use consolidation among customers trends toward managed care health care costs containment result us governments efforts reduce medicaid expenses managed care organizations continue grow influence company faces increased pricing pressure managed care organizations continue seek price discounts respect companys products international markets cost control methods including restrictions physician prescription levels patient reimbursements emphasis greater use generic drugs across board price cuts may decrease revenues internationally table contents material pending investigations company outcome could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company predict certainty outcome pending investigations subject may lead judgment settlement involving significant monetary award restrictions operations pricing sales marketing programs arrangements related business practices company participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission various state attorneys general offices many health care laws certain governmental entities operate including federal state anti kickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject company substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company also predict whether investigations affect marketing practices sales result could material adverse impact companys results operations cash flows financial condition business regardless merits outcomes investigations government investigations costly divert managements attention companys business may result substantial damage companys reputation please refer item legal proceedings report descriptions pending investigations legal matters adverse outcomes could negatively affect companys business unfavorable outcomes pending litigation matters including litigation concerning product pricing securities law violations product liability claims erisa matters patent intellectual property disputes antitrust matters could preclude commercialization products negatively affect profitability existing products materially adversely affect companys financial condition results operations subject company conditions affect business operations exclusion government reimbursement programs please refer item legal proceedings report descriptions significant pending litigation company subject governmental regulations failure comply well costs compliance regulations may adversely affect companys financial position results operations companys manufacturing facilities must meet stringent regulatory standards subject regular inspections cost regulatory compliance including associated compliance failures materially affect companys financial position results operations failure comply regulations include pharmacovigilance reporting requirements standards relating clinical laboratory manufacturing practices result delays approval drugs seizure recalls drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions example may company agreed fda entry consent decree resolve issues related compliance current good manufacturing practices certain companys facilities new jersey puerto rico consent decree work placed significant additional controls production release products sites increased costs table contents slowed production led reduction number products produced sites companys research development operations negatively impacted consent decree operations share common facilities manufacturing operations company also subject regulations including environmental health safety labor regulations developments following regulatory approval may decrease demand companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following rereview products already marketed uncertainties concerning safety labeling changes greater scrutiny advertising promotion recently clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products situations also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition following wake recent product withdrawals companies significant safety issues health authorities fda european medicines agency pharmaceuticals medicines device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications reviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase prevalence negative publicity regarding known side effects companys products could significantly reduce demand product may require company remove product market new products technological advances developed companys competitors may negatively affect sales company operates highly competitive industry many companys competitors conducting research development areas served companys current products products company process developing competitive developments may impact company include technological advances patents granted new products developed competitors new existing generic prescription andor otc products compete products scheringplough merck scheringplough cholesterol partnership addition possible doctors patients providers may favor products offered competitors due safety efficacy pricing reimbursement characteristics result company unable maintain sales products company often competes companies acquire license products whether early stage development already approved commercial sale company believes clinically commercially attractive may difficult company enter transactions one aspect companys business acquire license rights develop sell products companies may challenging acquire license products company believes clinically commercially attractive acceptable terms company competes opportunities companies often far greater financial resources company companys prospects may adversely affected unable obtain rights additional products acceptable terms table contents company relies third party relationships key products changes third parties outside control may impact business company relies third party relationships many key products time third parties involved may changes influences impact third parties outside control company may also directly indirectly impact companys business operation company operational financial control third parties may limited influence respect manner conduct businesses behave relationships company also many cases third parties may offer develop products may compete companys products conflicting interests relative company company operates global business exposes company additional risks adverse events could material negative impact results operations company operates countries nonus operations generate majority companys profit cash flow nonus operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing reimbursement restrictions restrictive governmental actions economic destabilization also fluctuations inflation interest rate foreign currency exchange rates impact scheringploughs consolidated financial results addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease insurance coverage product liability may become unavailable cost prohibitive company maintains insurance coverage deductibles selfinsurance reflect market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly however result increased product liability claims pharmaceutical industry availability third party insurance may become unavailable cost prohibitive company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws us foreign jurisdictions significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities companys us federal income tax returns period currently audit internal revenue service company may challenged irs tax authorities positions taken income tax returns although company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities due complexity tax contingencies ultimate resolution may result payments materially affect shareholders equity liquidity andor cash flow addition company may impacted changes tax laws including tax rate changes new tax laws revised tax law interpretations domestic foreign jurisdictions table contents item b unresolved staff comments none item properties scheringploughs corporate headquarters located kenilworth new jersey principal research facilities located kenilworth union summit new jersey palo alto california elkhorn nebraska principal manufacturing facilities follows location product type kenilworth new jersey pharmaceuticals consumer products omaha nebraska animal health cleveland tennessee consumer products puerto rico pharmaceuticals belgium pharmaceuticals ireland pharmaceuticals consumer products animal health mexico pharmaceuticals singapore pharmaceuticals company anticipates capital expenditures million next several years us pharmaceutical sciences center item legal proceedings material pending legal proceedings ordinary routine litigation incidental business scheringplough corporation subsidiaries property subject disclosed additional information legal proceedings including important financial information found litigation charges discussion note special charges note legal environmental regulatory matters contained item financial statements supplementary data item managements discussion analysis financial condition results operations k patent matters described patents trademarks intellectual property rights part business k intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect company dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages investigations massachusetts investigation us attorneys office district massachusetts investigating broad range companys sales marketing clinical trial practices programs along warrick pharmaceuticals warrick companys generic subsidiary investigation focused following alleged practices providing remuneration managed care organizations physicians others induce purchase schering pharmaceutical products offlabel marketing drugs submitting false pharmaceutical pricing information government table contents purposes calculating rebates required paid medicaid program company cooperating investigation outcome investigation could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company recorded liability million related investigation well investigations described awp investigations state litigation described awp litigation reasonably possible settlement investigation could involve amounts materially excess accrual awp investigations company continues respond existing new investigations department health human services department justice several states industry company practices regarding average wholesale price awp investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain government drug reimbursements based awp company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates pricing matters awp litigation company continues respond existing new litigation certain states private payors industry company practices regarding average wholesale price awp litigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following companys announcement fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed company certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege company failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege company failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares company stock may february complaint seeks compensatory damages behalf class court certified shareholder class october discovery ongoing shareholder derivative actions two lawsuits filed us district court district new jersey company certain officers directors former director seeking damages table contents behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints allege failure disclose material information breach fiduciary duty directors relating fda inspections investigations companys pricing practices sales marketing clinical trials practices lawsuits shareholder derivative actions purport assert claims behalf company two shareholder derivative actions pending us district court district new jersey consolidated one action august early stages product liability company previously disclosed defendant putative class action lawsuits involving alleged claims personal injuries arising plaintiffs ingestion phenylpropanolaminecontaining coughcold remedies ppa products class action lawsuits plaintiffs asserted claims personal injuries arising use laxative products sought refund purchase price laxatives purchased lawsuits dismissed resolved amounts paid resolve matters immaterial class action lawsuits currently exist concerning ppa claims individual lawsuits involving ppa products still pending company deems pending lawsuits immaterial aggregate company also previously disclosed defendant individual lawsuits relating recalled albuterol vanceril vancenase inhalers lawsuits dismissed resolved amounts paid resolve lawsuits immaterial erisa litigation march company served putative class action complaint filed us district court new jersey alleging company retired chairman ceo president richard jay kogan companys employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation kdur scheringploughs longacting potassium chloride product supplement used cardiac patients following commencement ftc administrative proceeding described alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages discovery ongoing antitrust matters kdur scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions k dur lederle upsher smith filed abbreviated new drug applications april ftc started administrative proceeding scheringplough upshersmith lederle alleging anticompetitive effects settlements administrative law judge issued decision patent litigation settlements complied law respects dismissed claims company ftc staff appealed decision full commission commission reversed decision administrative law judge ruling settlements violate antitrust laws full commission issued cease desist order imposing various injunctive restraints federal court appeals set aside commission ruling vacated cease desist order august ftc filed petition seeking hearing us supreme court senate finance committee inquiry january united states senate committee finance followed previous requests company request information companys practices relating educational grants company understands committee directed similar followup requests table contents pharmaceutical companies company cooperating committee process responding requests tax matters october irs auditors asserted two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september company made payments irs amount million income tax million interest company filed refund claims tax interest irs december following irss denial companys claims refund company filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase companys tax reserves adequate cover abovementioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania company entered fiveyear corporate integrity agreement cia disclosed note consent decree company subject obligations consent decree fda failure comply obligations cia consent decree result financial penalties discussion pending pharmacovigilance matters resulting pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea refer regulatory competitive environment company operates managements discussion analysis k matters biopharma contract dispute biopharma srl filed claim civil court rome july docket th chamber certain scheringplough subsidiaries complaint alleges scheringplough fulfill duties distribution supply agreements biopharma scheringplough subsidiary distribution scheringplough generic products manufactured biopharma hospitals pharmacists france item submission matters vote security holders applicable table contents executive officers registrant listed executive officers corporate officers company unless otherwise indicated held position indicated past five years officers serve one year successors duly appointed name title ge robert j bertolini executive vice president chief f inancial officer c ron cheeley senior vice president global human resources carrie cox executive vice president president global pharmaceuticals william j creelman vice president tax douglas j gingerella vice president controller fred hassan chairman chief executive officer thomas h kelly vice president corporate business development raul e kohan group head global specialty operations president animal health joseph j larosa vice president legal affairs ian mcinnes senior vice president global supply chain e kevin moore vice president treasurer cecil b pickett phd senior vice president president scheringplough research institute division anne renahan vice president global internal audits thomas j sabatino jr executive vice president general counsel karl salnoske vice president chief information officer brent saunders senior vice president global compliance business practices susan ellen wolf corporate secretary associate general counsel vice president corporate governance officers defined rule af securities exchange act mr bertolini joined company executive vice president chief financial officer mr bertolini partner pricewaterhousecoopers mr cheeley joined company senior vice president global human resources mr cheeley group vice president global compensation benefits pharmacia corporation ms cox joined company executive vice president president global pharmaceuticals ms cox executive vice president president global prescription business pharmacia corporation table contents mr creelman joined company vice president tax mr creelman senior tax counsel pfizer mr creelman assistant vice president international tax cigna corporation vice president tax us smithkline beecham mr gingerella named vice president controller mr gingerella vice president corporate audits mr hassan joined company chairman board chief executive officer mr hassan chairman board chief executive officer pharmacia corporation mr kelly became vice president corporate business development mr kelly vice president controller mr larosa became vice president legal affairs mr larosa staff vice president secretary associate general counsel dr mcinnes joined company senior vice president global supply chain dr mcinnes senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc dr pickett named senior vice president dr pickett joined scheringplough research institute executive vice president discovery research scheringplough research institute named president scheringplough research institute ms renahan joined company vice president global internal audits ms renahan executive director controller eisai inc mr sabatino joined company executive vice president general counsel mr sabatino senior vice president general counsel baxter international inc mr salnoske joined company vice president chief information officer mr salnoske ceo adaptive trade mr saunders joined company senior vice president global compliance business practices mr saunders partner pricewaterhousecoopers ms wolf named vice president corporate secretary associate general counsel held various positions scheringploughs law department senior attorney delta airlines table contents part ii item market registrants common equity related stockholder matters common share dividends share price data approximate number holders record set forth item financial statements supplementary data k following table provides information respect purchases company common shares fourth quarter issuer purchases equity securities tot al number maxi mum number shares purchased shares may average part publicly yet purchased total number price paid announced plans plans period shares purchased per share programs programs october throu gh october na na november november na na december december na na total october december na na shares included table repurchased pursuant companys stock incentive program represent shares delivered company option holders payment exercise price tax withholding obligations connection stock options stock awards table contents item selected financial data mi llions exce pt per sha figures nd percen tages operating results net sales incomeloss income taxes net incomeloss net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share research development expenses depreciation amortization expenses financial position cash flows property net total assets longterm debt shareholders equity capital expenditures financial statistics net incomeloss percent net sales return average shareholders equity net book value per common share data cash dividends per common share cash dividends common shares cash dividends preferred shares average shares outstanding used calculating diluted earningsloss per common share average shares outstanding used calculating basic earningsloss per common share common shares outstanding yearend include special charges respectively see note special charges item financial statements supplementary data k additional information assumes conversion preferred shares approximately million common shares million common shares item managements discussion analysis financial condition results operations executive summary overview company scheringplough company discovers develops manufactures markets medical therapies treatments enhance human health company also markets leading consumer brands overthecounter otc foot care sun care markets operates global animal health business table contents researchbased pharmaceutical company core strategy scheringplough invest substantial funds scientific research goal creating therapies treatments important medical commercial value consistent core strategy company increasing investment research development trend expected continue historic levels greater research development activities focus mechanisms treat serious diseases high rate failure inherent research result high risk funds invested research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase commercial phase may take decade two sources new products products acquired acquisition licensing arrangements products companys latestage research pipeline respect acquisitions licensing limited opportunities obtaining licensing critical latestage products limited opportunities typically require substantial amounts funding company competes opportunities companies often greater financial resources accordingly may challenging company acquire license critical latestage products positive material financial impact company supports commercialized products manufacturing sales marketing efforts company also moving forward additional investments enhance infrastructure business including capital expenditures development process products moved drug discovery pipeline markets information technology systems postmarketing studies monitoring companys financial situation continues improve discussed companys cholesterol franchise products vytorin zetia primary drivers improvement zetia companys novel cholesterol absorption inhibitor vytorin combination zetia zocor merck co incs merck statin medication two products launched joint venture company merck zetia ezetimibe marketed europe ezetrol marketed use either together statins treatment elevated cholesterol levels zetia ezetrol launched countries vytorin ezetimibesimvastatin marketed inegy internationally launched countries including united states company currently expects cholesterol franchise continue grow financial commitment compete cholesterol reduction market shared merck profits sales vytorin zetia also shared merck operating results joint venture merck recorded using equity method accounting outside joint venture merck japanese market bayer healthcare comarket companys cholesterol absorption inhibitor zetia upon approval due backlog new drug applications japan company precisely predict timing approval cholesterolreduction market single largest pharmaceutical category world vytorin zetia competing market combined basis products continued grow terms market share franchise two products together captured percent new prescriptions us cholesterol management market based january ims data vytorin currently ranks thirdleading prescription product treating patients high cholesterol based new prescriptions date physicians written million total prescriptions vytorin us zetia sales continue grow even vytorin grows market share companys results operations cash flows driven significantly performance vytorin zetia result companys ability generate profits predominantly dependent upon performance vytorin zetia cholesterol franchise dependence expected continue time equity income cholesterol joint venture million net income available common shareholders million additional information regarding joint venture merck also included note equity income table contents cholesterol joint venture item financial statements supplementary data k although expected operating cash flow existing cash investments including funds repatriated american jobs creation act ajca fund companys operations near intermediate term discussed detail future cash flows also dependent upon performance vytorin zetia company must generate profits cash flows maintain enhance infrastructure business discussed sales products may impacted introduction new innovative competing treatments generic versions existing products regard company expects generic forms pravachol zocor two existing wellestablished cholesterolmanagement products introduced us lose patent protection beginning generics introduced international markets company reasonably predict effect introduction generic forms cholesterol management products may vytorin zetia although decisions government entities managed care groups groups concerning formularies reimbursement policies could potentially negatively impact dollar size andor growth cholesterol management market including vytorin zetia material change sales market share vytorin zetia would significant impact companys operations cash flow remicade prescribed treatment rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis recently gained approval europe psoriasis remicade companys second largest marketed pharmaceutical product line cholesterol franchise product licensed manufactured centocor inc johnson johnson company company exclusive marketing rights product outside us japan china including hong kong taiwan indonesia third quarter company exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody territories remicade golimumab currently phase iii trials centocor believes rights golimumab expire company believes rights extend beyond parties working together move forward collaboration golimumab steps taken resolve difference opinion expiration date typical pharmaceutical industry company licenses manufacturing marketing andor distribution rights certain products others also manufactures markets andor distributes products owned others pursuant licensing joint venture arrangements time third parties involved additional factors relating third party outside control company may create positive negative impacts company vytorin zetia remicade subject arrangements key companys current business financial performance addition potential strategic alternatives may impacted change control provisions arrangements could result vytorin zetia acquired merck remicade reverting back centocor change control provision relating vytorin zetia included contract merck filed exhibit q companys k change control provision relating remicade contained contract centocor filed exhibit u companys k period company experienced number negative events strained continue strain companys financial resources explained companys overall financial situation began improve negative events remain relevant understand companys current challenges negative events included limited following matters entered formal consent decree fda agreed implement cgmp work plan revalidate manufacturing processes certain manufacturing sites us puerto rico company completed significant steps cgmp work plan validation actions required december consent decree subject certification external third party review approval fda terms table contents decree provided fda notified company significant violation fda law regulations decree five year period since decrees entry may may company may petition court decree dissolved fda oppose companys petition company incurred significant costs associated manufacturing compliance efforts part consent decree incremental compliance costs incurred completion third party certification fda review approval process addition company found necessary discontinue certain older profitable products outsource products switch claritin us beginning december prescription otc status switch coupled private label competition resulted substantially lower overall sales product starting well lower average unit selling price product ongoing intense competition companys exposure powerful retail purchasers also increased market shares sales levels certain company products fell significantly experienced increased competition products continue compete declining volatile markets investigations certain companys sales marketing practices us attorneys offices massachusetts pennsylvania company made payments totaling million us attorneys office eastern district pennsylvania settlement investigation response matters beginning april board directors named fred hassan new chairman board chief executive officer scheringplough corporation leadership new leadership team recruited six eightyear fivephase action agenda formulated goal stabilizing repairing turning around company october company announced entered third turnaround phase action agenda beginning turnaround phase defined achieving three consecutive quarters sales earnings growth excluding special items current state business net sales billion increase billion percent period increase driven primarily growth remicade pegintron nasonex temodar animal health business us sales contribution antibiotics avelox cipro products agreement bayer became effective october foreign exchange contributed percent sales increase sales marketing costs increased due addition bayer sales representatives increased selling expenses europe support continued launches vytorin zetia increased promotional spending primarily nasonex asmanex products agreement bayer company net income available common shareholders million compared net loss available common shareholders million net income available common shareholders included charge increase litigation reserves million resulting total reserve million representing companys current estimate resolve massachusetts investigation well investigations disclosed awp investigations state litigation disclosed awp litigation note legal environmental regulatory matters item financial statements supplementary data addition net income available common shareholders also included research development expense approximately million million net tax license rights develop commercialize golimumab net loss available common shareholders included pretax research development charge million license garenoxacin toyama chemical company ltd tax expense million included table contents provision taxes related planned repatriation unremitted foreign earnings american jobs creation act valuation reserve net deferred tax assets us many companys manufacturing sites operate capacity companys manufacturing sites subject consent decree remained open company performing revalidation cgmp work plan obligations decree however consent decree work placed significant additional controls production release products sites increased costs slowed production led reduction product mix sites companys research development operations negatively impacted consent decree operations share common facilities manufacturing operations although certain costs associated third party certifications decrease completion work plan certified financial impacts continue costs new processes continue used reduced product mix volumes sites companys manufacturing cost base relatively fixed actions part management significantly reduce companys manufacturing infrastructure involve complex issues cases shifting products manufacturing plants take many years due construction revalidation registration requirements management continues review carrying value certain manufacturing assets indications impairment future events decisions may lead asset impairments andor related costs company repatriated approximately billion previously unremitted foreign earnings reduced tax rate provided american jobs creation act ajca repatriating funds ajca benefits company following ways companys us operations currently incur significant negative cash flow operating cash flows existing cash investments including repatriations made ajca expected provide company ability fund us cash needs near intermediate term company continue use repatriated funds ajca qualified spending us operations produced us tax net operating loss us nol carryforwards approximately billion ajca qualifying repatriations reduce us tax losses company cash necessary fund us cash needs potential benefit able carry forward us nols reduce future us taxable income potential future benefit could significant dependent company achieving profitability us discussion operating results net sales significant portion net sales made major pharmaceutical health care product distributors major retail chains us consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors consolidated net sales totaled billion increase billion percent compared consolidated net sales reflected higher volumes remicade pegintron nasonex temodar inclusion full year sales avelox cipro addition foreign exchange favorable impact percent consolidated net sales billion decreased million percent compared primarily reflecting volume declines offset favorable foreign exchange rate impact percent table contents net sales years ended december follows incr ease decr ease ollars million prescription pharmaceuticals remicade pegintron nasonex clarinex aerius temodar claritin rxa rebetol integrilin intron avelox nm nm subutex caelyx cipro nm nm elocon pharmaceutical consumer health care otcb foot care sun care animal health consolidated net sales certain prior year amounts reclassified conform current year presentation n meaningful percentage amounts shown include international sales claritin rx b includes otc claritin respectively international net sales remicade treatment immunemediated inflammatory disorders rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis million percent million due greater demand expanded indications continued market growth sales remicade million million percent compared due greater medical use expanded indications european markets near future additional competitive products indications referred likely introduced global net sales pegintron powder injection pegylated interferon product treating hepatitis c increased million percent million compared due december launch pegintron rebetol combination therapy japan sales japan benefited significant number patients waiting approval pegintron beginning treatment patient warehousing comparisons unfavorably impacted absence patient warehousing anticipated government mandated price reductions japan result factors sales may decline materially sales pegintron us decreased primarily reflecting decline overall market sales pegintron decreased table contents million percent million due primarily loss market share reflecting entrance competitors new products hepatitis c market global net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies rose percent million product captured greater us international market share versus period us sales benefited increased promotional effort introduction beginning january new scentfree alcoholfree formulation nasonex nasal spray sales nasonex increased percent versus million primarily due international sales growth favorable prior year trade inventory comparisons us tempered decline us market share generic flonase fluticasone propionate approved may unfavorably impact corticosteroid nasal spray market global net sales clarinex marketed aerius many countries outside us treatment seasonal outdoor allergies yearround indoor allergies decreased million percent versus sales us decreased million percent versus due reduced market share declining market september generic allegra fexofenadine introduced us continue negatively affect antihistamine market including clarinex sales outside us increased million percent million due primarily market share gains global net sales clarinex million essentially flat versus sales outside us increased percent million due market share gains continued conversion prescription claritin us sales decreased percent million due continued contraction us prescription antihistamine market following launch otc claritin branded nonbranded nonsedating antihistamines coupled market share declines global net sales temodar capsules treatment certain types brain tumors increased million percent million due increased utilization treating newly diagnosed glioblastoma multiforme gbm prevalent form brain cancer new indication granted us fda approval march rapidly adopted us physicians june temodar received approval european commission use combination radiotherapy gbm patients member states well iceland norway japan temodar granted priority review regulatory application treat malignant glioma fourth quarter sales temodar increased million percent million due increased market penetration growth rates temodar may moderate going forward significant market penetration already achieved treatment gbm especially us international net sales prescription claritin increased million percent million due launch claritin reditabs japan coupled unusually severe japanese allergy season may recur international sales prescription claritin million decrease percent compared due continued conversion clarinex global net sales rebetol capsules use combination intron pegintron treating hepatitis c increased million percent million due primarily launch pegintron rebetol combination therapy japan december sales japan benefited significant number patients waiting approval pegintron beginning treatment patient warehousing comparisons unfavorably impacted absence patient warehousing result sales may decline materially rebetol may also subject larger average government mandated price reductions japan sales rebetol decreased percent million due launch generic versions rebetol us april increased price competition outside us global net sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndrome sold primarily us company million compared million sales integrilin us essentially flat versus sales outside us decreased million reflecting return table contents european marketing rights millennium pharmaceuticals inc millennium sales integrilin increased million percent versus due increased patient utilization effective september company restructured integrilin copromotion agreement millennium terms restructured agreement company acquired exclusive us development commercialization rights integrilin exchange upfront payment million royalties integrilin sales restructured agreement calls minimum royalty payments million per year millennium global net sales intron injection chronic hepatitis b c antiviral anticancer indications decreased percent million due conversion pegintron japan sales intron decreased percent million due primarily lower demand net sales avelox fluoroquinolone antibiotic treatment certain respiratory skin infections sold primarily us scheringplough result companys license agreement bayer million sales avelox represented initial three months sales agreement bayer effective october international net sales subutex tablets treatment opiate addiction increased percent million due increased market penetration sales subutex million increase percent due increased market penetration expected subutex encounter generic competition near future international sales caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increased percent million reflecting adoption ovarian cancer metastatic breast cancer indications sales caelyx increased percent versus million reflecting initial adoption metastatic breast cancer indication net sales cipro fluoroquinolone antibiotic treatment certain respiratory skin urinary tract infections sold primarily us scheringplough result companys license agreement bayer million sales cipro represented initial three months sales agreement bayer global net sales elocon cream mediumpotency topical steroid decreased percent million reflecting generic competition introduced us first quarter generic competition expected continue adversely affect sales product pharmaceutical net sales include large number lower sales volume prescription pharmaceutical products several products sold limited markets outside us many multiple source products longer protected patents products include treatments respiratory cardiovascular dermatological infectious oncological diseases global net sales consumer health care products include otc foot care sun care products billion sales otc claritin million decrease million percent reflecting adverse impact sales claritind due restrictions retail sale otc products containing pseudoephedrine pse came effect sales claritind may continue adversely affected recent future restrictions retail sale products addition otc claritin continues face competition private label branded loratadine net sales sun care products increased million percent primarily due launch new coppertone continuous spray products coupled stronger overall suncare season us net sales foot care products increased million percent due primarily new memory fit insoles insole products net sales consumer health care products increased million percent compared due primarily strong performance dr scholls freeze away foot care products table contents company sells numerous nonprescription upper respiratory products contain pse fdaapproved ingredient relief nasal congestion companys annual north american sales nonprescription upper respiratory products contain pse totaled approximately million million approximately million products include claritind products well drixoral coricidin chlortrimeton products company understands pse used illicit manufacture methamphetamine dangerous addictive drug december states canada mexico enacted regulations concerning nonprescription sale products containing pse including limiting amount products purchased one time requiring products located behind pharmacists counter stated goal deterring illicitillegal manufacture methamphetamine additional states enacted limits quantity pse person possess one state recently enacted legislation regulates pse products prescription status also us federal government proposed legislation placing restrictions sale products containing pse major us retailers customers company voluntarily placed nonprescription products containing pse behind pharmacy counter stores whether required local law sales nonprescription pse products million approximately percent compared company continues monitor developments area could negative impact operations financial results noted regulations relate sale prescription products clarinexd products contain pse global net sales animal health products increased percent million increased sales reflected strong growth core brands across geographic species areas led products serving us cattle market including nuflor vaccine business increased sales also due part better product supply us sales growth included favorable foreign exchange impact percent company expects growth rate moderate due increased competition including generic products global net sales animal health products increased percent included favorable foreign exchange impact percent certain situations positive impact sales net income may recur include favorable effect foreign exchange patient warehousing benefit pegintron rebetol related launch pegintron japan unusually severe allergy season japan benefited reported sales prescription claritin generic allegra fexofenadine introduced us expected negative impact us clarinex sales generic flonase fluticasone propionate approved may unfavorably impact corticosteroid nasal spray market growth remicade may also affected increased competition addition company expects growth rate animal health business moderate due increased competition including generic products table contents costs expenses equity income summary costs expenses equity income years ended december follows incr ease dec rease ollars million cost sales selling general administrative sga research development rd expenseincome net nm nm special charges nm nm equity income cholesterol joint venture nm nm n meaningful percentage substantially sales cholesterol products included companys net sales results sales reflected equity income cholesterol joint venture addition due virtual nature joint venture company incurs substantial selling general administrative expenses captured equity income included companys statements consolidated operations result companys gross margin ratios sga expenses rd expenses percentage net sales reflect impact joint ventures operating results gross margin gross margin increased compared percent percent primarily due supply chain process improvements increased sales highermargin products favorable impact foreign exchange partly offset higher royalties related bayer products beginning september royalties integrilin restructuring integrilin agreement substantially offsetting effects generally increasing cost sales due increased royalties offset reduced selling general administrative expenses gross margin unfavorably impacted full year increased royalties restructured agreement gross margin decreased compared percent percent primarily due lower production volumes coupled increased spending related fda consent decree manufacturing compliance spending efforts upgrade companys global infrastructure absence european losec revenues change product sales mix including sales bayer licensed products contributed unfavorable comparison well selling general administrative selling general administrative expenses sga increased percent billion versus billion increase primarily due addition fourth quarter bayer sales representatives increased selling expenses europe support continued launch vytorin zetia increased promotional spending primarily nasonex asmanex products agreement bayer sga expenses increased percent billion billion primarily due expansion sales field force higher employeerelated costs unfavorable impact foreign exchange partially offset lower promotional spending research development research development rd spending increased percent billion representing percent net sales included million charge conjunction companys exercise rights develop commercialize golimumab rd spending included million charge conjunction license toyama chemical company ltd garenoxacin generally changes rd spending reflect timing companys funding internal research table contents efforts research collaborations various partners discover develop steady flow innovative products company believes strong early development pipeline across widerange therapeutic areas preclinical phase compounds additionally later phase growthdrivers pipeline enter phase iii eg thrombin receptor antagonist vicriviroc hcv protease inhibitor company anticipates approximate doubling annual patient enrollment clinical trials next years versus levels company expects rd spending increase compared prior years due progression companys earlystage pipeline increased clinical trial activity maximize companys chances successful development new products company began development excellence initiative build talent critical mass create uniform level excellence deliver highpriority programs within rd expenseincome net expenseincome net million lower reflected higher net interest income due higher interest rates cash equivalents shortterm investments increase expenseincome net versus primarily result higher net interest expense due debt issuances special charges components special charges follows dollars million litigation charges employee termination costs asset impairment charges litigation charges litigation reserves increased million increase resulted total reserve million massachusetts investigation well investigations disclosed awp investigations state litigation disclosed awp litigation note legal environmental regulatory matters representing companys current estimate resolve matter additional information regarding litigation reserves also included note legal environmental regulatory matters item financial statements supplementary data k litigation reserves increased million primarily result investigations companys sales marketing practices employee termination costs august company announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program retired december total cost program approximately million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants table contents million amounts recognized program million million million respectively additional amounts expected recognized program termination costs associated verp totaled million million million respectively following summarizes activity accounts related employee termination costs emplo yee termination costs dollars millions special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december asset impairment charges year ended december company recognized asset impairment charges million related primarily consolidation companys us biotechnology organizations company recorded asset impairment charges million related primarily shutdown small european research development facility asset impairment charges million related closure manufacturing facility united kingdom writedown production equipment related products longer going produced manufacturing site operating fda consent decree write drug license sun care trade name expected cash flows support carrying value equity income cholesterol joint venture global cholesterol franchise sales include sales made company cholesterol joint venture merck vytorin zetia totaled billion billion million respectively sales comparison benefited us launch vytorin second half franchise two products combined passed percent share level new prescriptions us cholesterol management market based january ims data vytorin launched countries including us august zetia approved countries launched countries company utilizes equity method accounting joint venture sharing income operations based upon percentages vary product sales level country companys allocation joint venture income increased milestones earned merck scheringplough partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico joint venture reimburses partner predefined amount physician details set annual basis company table contents reports reimbursement part equity income cholesterol joint venture reimbursement represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directto consumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners equity income cholesterol joint venture totaled million million million respectively equity income comparison benefited us launch vytorin second half company recognized milestones merck million million million respectively million milestone related certain european approvals vytorin ezetimibesimvastatin million milestone related approval ezetimibesimvastatin mexico million milestone related certain european approvals zetia amounts included equity income certain conditions specified joint venture agreements merck company could earn additional milestones totaling million noted company incurs substantial selling general administrative costs reflected equity income cholesterol joint venture instead included overall cost structure company provision income taxes tax expense million million million respectively overall income tax expense net benefit described primarily related foreign taxes include benefit related us net operating losses nols company established valuation allowance net us deferred tax assets including benefit us nols management conclude likely benefit us net deferred tax assets realized december company us nol carryforwards totaling approximately billion companys tax provision year ended december includes us federal income tax benefit approximately million result irs notice issued august provisions notice resulted reduction previously accrued tax liability attributable ajca repatriation also reduced us nols carried forward subsequent years income tax provision includes charge approximately million related foreign taxes million state taxes benefit million us federal taxes primarily related irs notice mentioned january internal revenue service irs completed examination companys federal income tax returns company made cash payment third quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charges payment fully satisfied liability associated tax examination consistent previously recorded reserves irs currently examining companys federal income tax returns table contents net incomeloss available common shareholders net income available common shareholders includes deduction preferred stock dividends million related issuance percent mandatory convertible preferred stock august net loss available common shareholders includes deduction preferred stock dividends million liquidity financial resources discussion cash flow ye ars e nded december dollars millions cash flow operating activities cash flow investing activities cash flow financing activities cash flow operating activities worldwide basis approximated cash payments capital expenditures dividends international operations generate cash excess local cash needs however us operations cash needs well excess cash generated us us operations must fund dividend payments majority research development costs us capital expenditures years prior overall us cash needs funded primarily operations cash requirements us including operating cash needs capital expenditures tax payments dividends common preferred shares approximated billion consolidated operating activities generated million cash compared use million increase primarily due higher net income timing payments special charges related litigation partially offset increase accounts receivable due sales growth payments tax authorities tax liabilities related repatriation foreign earnings ajca approximately million tax deposits million anticipated settlement certain tax contingencies tax years tax charges related ajca expensed operating cash flow favorably impacted us tax refund million result loss carry back however cash flow unfavorably impacted million payment us government tax deficiency related certain transactions tax years payment million settlement agreement us attorneys office eastern district pennsylvania operating activities provided approximately million cash amount includes cash flow benefit reduction accounts receivable following end sales claritin prescription product us amount also includes million payment terms fda consent decree net cash used investing activities million primarily related million capital expenditures purchase intangible assets million partially offset proceeds sales property equipment million net reduction shortterm investments million net cash used investing activities million included capital expenditures million net purchases investments million partially offset cash proceeds million transfer license rights million dispositions property equipment net cash used financing activities million compared net cash provided financing activities billion uses cash financing activities include table contents payment dividends common preferred shares million repayment billion commercial paper borrowings partially offset proceeds million bank debt incurred foreign subsidiary related funding portion repatriations ajca net cash provided financing activities reflected proceeds billion preferred stock issuance million increase shortterm borrowings partially offset payment dividends common preferred shares million companys financial situation begun improve company moving forward additional investments enhance infrastructure business includes expected capital expenditures million next several years pharmaceutical sciences center center allow company streamline integrate companys drug development process products moved drug discovery pipeline market additional related expenditures upgrade equipment staffing center us operations continue generate negative cash flow payments regarding litigation investigations could increase cash needs operating cash flows existing cash investments including repatriations made ajca expected provide company ability fund cash needs including us cash needs near intermediate term total cash cash equivalents shortterm investments less total debt approximately billion december august company issued percent mandatory convertible preferred stock see note shareholders equity item financial statements supplementary data received net proceeds billion deducting commissions discounts underwriting expenses proceeds used reduce shortterm commercial paper borrowings pay tax litigation settlement amounts litigation costs fund operating expenses shareholder dividends capital expenditures preferred stock issued companys billion shelf registration december million remains registered unissued shelf registration borrowings credit facilities november company issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due proceeds offering billion used general corporate purposes including repaying commercial paper outstanding us upon issuance notes rated moodys investors service moodys credit watch negative implications standard poors sp interest rates payable notes subject adjustment rating assigned notes either moodys sp downgraded respectively interest rate payable series notes would increase see note shortterm borrowings longterm debt commitments item financial statements supplementary data k additional information july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december therefore december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent adjustment interest rate payable notes increased companys interest expense approximately million annually company revolving credit facility syndicate major financial institutions march company negotiated increase bank commitments billion billion changes basic terms preexisting credit facility concurrently increase commitments facility company terminated early separate million line credit would matured may outstanding balance facility time terminated table contents existing billion credit facility matures may requires company maintain total debt total capital ratio percent credit line available general corporate purposes considered support companys commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december million drawn facility wholly owned international subsidiary purposes funding ajca related repatriations addition aforementioned credit facility company entered million credit facility fourth quarter drawn december credit facility utilized whollyowned international subsidiary fund repatriations ajca credit facility requires company maintain total debt total capital ratio percent borrowings payable later november funds borrowed facility subsequently repaid may reborrowed credit facility borrowings classified shortterm borrowings company intends repay amounts next twelve months december shortterm borrowings including credit facilities mentioned totaled billion billion respectively commercial paper outstanding december million billion respectively weightedaverage interest rate shortterm borrowings december percent percent respectively credit ratings companys current unsecured senior credit ratings outlook follows senior unsecured credit ratings long term sho rtterm ou tlook moodys investors service baa p n egative standard poors negative fitch ratings f negative commercial paper ratings discussed significantly affected companys ability issue rollover outstanding commercial paper borrowings time however company believes ability commercial paper issuers company one shortterm credit ratings p moodys sp andor f fitch issue rollover outstanding commercial paper times less companies higher shortterm credit ratings addition total amount commercial paper capacity available issuers typically less higherrated companies company maintains sizable lines credit commercial banks well cash shortterm investments held us international subsidiaries serve alternative sources liquidity support commercial paper program companys credit ratings could decline current levels impact decline could reduce availability commercial paper borrowing would increase interest rate companys short longterm debt discussed company believes existing cash balances cash generated operations allow company fund us cash needs near intermediate term table contents contractual obligations payments due period companys known contractual obligations december follows paymen ts due per iod less total year years years years dolla rs million shortterm borrowings current portion longterm debt longterm debt obligations operating lease obligations purchase obligations advertising contracts research contracts capital expenditure commitments purchase obligations obligations total longterm debt obligations include million aggregate principal amount percent senior unsecured notes due million aggregate principal amount percent senior unsecured notes due excludes interest obligations see note shortterm borrowings longterm debt commitments item financial statements supplementary data k additional information research contracts include potential milestone payments made since payments contingent occurrence certain events table also excludes research contracts cancelable company without penalty purchase obligations consist cancelable noncancelable inventory expense items caption includes obligations based undiscounted amounts estimated payments certain companys pension deferred compensation plans preferred stock dividends contractual obligations regulatory competitive environment company operates company subject jurisdiction various national state local regulatory agencies regulations described detail part item business k regulatory compliance complex regulatory standards including good clinical practices good laboratory practices good manufacturing practices vary jurisdiction constantly evolving regulatory compliance costly regulatory compliance also impacts timing needed bring new drugs market market drugs new indications failure comply regulations result delays approval drugs seizure recall drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions regulatory compliance cost compliance failures material impact companys results operations cash flows financial condition since company working us fda consent decree resolve issues involving companys compliance current good manufacturing practices cgmp certain table contents manufacturing sites new jersey puerto rico see details note consent decree item financial statements supplementary data k terms consent decree company made payments totaling million end company completed revalidation programs bulk active pharmaceutical ingredients finished drug products well significant steps cgmp work plan accordance schedules required consent decree companys completion cgmp work plan currently pending certification third party expert whose certification turn subject acceptance fda terms decree provided fda notified company significant violation fda law regulations decree five year period since decrees entry may may company may petition court decree dissolved fda oppose companys petition company subject pharmacovigilance reporting requirements many countries jurisdictions including us european union eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea cited serious deficiencies reporting processes company continued work longterm action plan rectify deficiencies provided regular updates emea fourth quarter local uk emea regulatory authorities conducted follow inspection assess companys implementation action plan inspectors acknowledged progress made since also continued note significant concerns quality systems supporting companys pharmacovigilance processes similarly follow inspection companys clinical trial practices uk inspectors identified issues respect companys management clinical trials related pharmacovigilance practices company intends continue upgrading skills processes systems clinical practices pharmacovigilance company remains committed accomplish work invest significant resources area february company announced initiative building clinical excellence trial design execution tracking strengthen companys scientific compliance rigor global basis company know action emea national authorities take response inspections possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products recently clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products addition situations raised concerns among prescribers patients relating safety efficacy pharmaceutical products general company personnel regular open dialogue fda regulators review product labels materials regular basis new information becomes known following wake recent product withdrawals companies significant safety issues health authorities fda emea pmda increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising table contents similarly major health authorities including fda emea pmda also increased collaboration amongst especially regard evaluation safety benefitrisk information media attention also increased current environment health authority regulatory action one market safety labeling change may regulatory prescribing marketing implications markets extent previously seen health authorities pmda japan publicly acknowledged significant backlog workload due resource constraints within agency backlog caused long regulatory review times new indications products including initial approval zetia japan added uncertainty predicting approval timelines markets pmda committed correcting backlog expected continue foreseeable future fda issued final rule removing essential use designation albuterol cfc products removal designation requires cfc albuterol products including companys proventil cfc removed market later december necessitate transition marketplace albuterol cfc proventil albuterol hfa proventil hfa later end difficult predict impact transition albuterol marketplace companys products uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect companys operations effect regulatory approval processes operations predicted company nevertheless achieved significant number important regulatory approvals since including approvals vytorin clarinex clarinex reditabs clarinex new indications temodar nasonex significant approvals since include asmanex dpi dry powder inhalation united states noxafil eu pegintron japan new indications remicade company also number significant regulatory submissions filed major markets awaiting approval described specifically note legal environmental regulatory matters item financial statements supplementary data k pricing sales marketing programs arrangements related business practices company participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject company substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company also predict whether investigations affect marketing practices sales result could material adverse impact companys results operations cash flows financial condition business us many companys pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts us market company pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs international markets company operates environment government mandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price table contents cuts methods control costs example japan generally enacts biennial price reductions expected occur pricing actions occur certain major european markets since company unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals us effect operations cash flows reasonably estimated similarly effect operations cash flows decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated company predict net effect medicare prescription drug benefit markets sales new medicare drug benefit medicare part took effect january offers voluntary prescription drug coverage subsidized medicare million medicare beneficiaries competing private prescription drug plans pdps medicare advantage plans many companys leading drugs already covered medicare part b eg temodar integrilin intron medicare part b provides payment physician services include prescription drugs administered along physician services manner drugs reimbursed medicare part b may limit companys ability offer larger price concessions make large price increases drugs scheringplough drugs relatively small portion sales medicare population eg clarinex hepatitis c franchise company could experience expanded utilization vytorin zetia new drugs companys rd pipeline greater consequence company may legislations impact pricing rebates discounts market pharmaceutical products competitive companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted outlook relates financial performance company anticipates sales profits pivotal cholesterol franchise continue grow companys gross margin improved result among things operating efficiencies plants reduced spending related consent decree improvement gross margin expected moderate improvements may offset royalty payments partners company anticipates rd expenses may grow faster rate net sales depend timing studies success phase ii trials underway thrombin receptor antagonist hepatitis protease inhibitor hiv drug vicriviroc company moves forward action agenda additional investments anticipated enhance infrastructure areas clinical development pharmacovigilance information technology risks described item risk factors could cause actual results differ expectations provided section impact recently issued accounting standards november fasb issued statement financial accounting standard sfas inventory costs sfas requires abnormal spoilage expensed period incurred table contents opposed inventoried amortized income inventory usage fixed production facility overhead costs allocated normal production level facility company implemented sfas fourth quarter implementation sfas material impact companys financial statements march fasb issued interpretation fin sfas accounting conditional asset retirement obligations clarify term conditional asset retirement obligations used sfas term refers legal obligation perform asset retirement activity timing andor method settlement conditional future event may may within control entity accordingly company required recognize liability fair value conditional asset retirement obligation fair value liability reasonably estimated interpretation effective later end fiscal year ending december retroactive application required company implemented fin fourth quarter implementation fin material impact companys financial statements december fasb issued sfas revised sharebased payment sfas r sfas r effective company january sfas r requires companies recognize compensation costs related sharebased transactions well compensation based market performance company shares fair value basis company adopt sfas r first quarter using modified prospective method modified prospective method requires company recognize compensation costs sharebased grants made january well unrecognized cost unvested awards date adoption upon adoption sfas r company recognize sharebased compensation costs service period earlier employees retirement eligibility date stated vesting period award grants issued retirement eligible employees prior adoption sfas r company recognize compensation costs stated vesting period acceleration unrecognized compensation costs upon retirement employee sfas r also amends sfas statement cash flows require excess tax benefits reflected operating cash flows reflected financing cash flows note summary significant accounting policies item financial statements supplementary data k presents pro forma disclosures reflecting effect net incomeloss stock based compensation applied sfas accounting stockbased compensation fair value method result adoption sfas r companys compensation expense stock options deferred stock units expected consistent pro forma amounts could lower based timing number individual grants companys stock price assumptions necessary estimate fair value addition company two compensation plans accounted sfas r liabilitybased plans ultimate cash payout liabilitybased plans based companys stock price performance compared stock price performance peer group change accounting required sfas r result cumulative effect million income january order recognize difference companys previously accrued liability reported accounting principles board apb opinion number fair value liability plans future operating results impacted fluctuation fair value liability plans required remeasured reporting date critical accounting policies following accounting policies considered significant changes certain judgments assumptions inherent policies could affect companys financial statements revenue recognition rebates discounts returns provision income taxes table contents impairment intangible assets property accounting pensions postretirement benefit plans accounting legal regulatory matters revenue recognition companys pharmaceutical products sold direct purchasers eg wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies well indirect purchasers market participants eg managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers company recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue company estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period estimates recorded prior periods reevaluated part process reliable estimates items made company defers recognition revenue revenue recognition new products based specific facts circumstances including estimated acceptance rates established products similar marketing characteristics absent ability make reliable estimates rebates discounts returns company would defer revenue recognition product discounts granted based terms arrangements wholesalers managedcare organizations government purchasers well market conditions including prices charged competitors rebates estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis third party demand market research data well internally generated information data information provided purchasers obtained third parties subject inherent limitations accuracy validity sales returns generally estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part formulation return reserves company entered agreements major us pharmaceutical wholesalers agreements deal number commercial issues product returns timing payment processing chargebacks quantity inventory held wholesalers respect quantity inventory held wholesalers agreements provide financial disincentive wholesalers acquire quantities product excess necessary meet current patient demand use monitoring noted agreements company expects avoid situations companys shipments product reflective current demand rebates discounts returns rebate accruals federal state governmental programs million december million december commercial discounts rebate accruals table contents million december million december rebate accruals established period related revenue recognized resulting reduction sales establishment liabilities included total current liabilities case governmental rebate programs companys payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy companys obligations additional information governmental inquiries focused part calculation rebates contained note legal environmental regulatory matters item financial statements supplementary data k addition possible result governmental challenges changes interpretive guidance actual rebates could materially exceed amounts accrued following summarizes activity accounts related accrued rebates sales returns discounts year e nded year e nded december december dollars illions accrued rebates returns discounts beginning period provision rebates payments provision returns returns provision discounts discounts granted accrued rebates returns discounts end period management makes estimates uses assumptions recording accruals actual amounts paid current period consistent previously estimated certain prior year amounts conformed reflect current year presentation provision income taxes december taxes provided approximately billion undistributed earnings international subsidiaries company considers earnings permanently reinvested international subsidiaries companys potential tax exposures result varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property although companys cross border arrangements affiliates based upon internationally accepted standards tax authorities various jurisdictions may disagree subsequently challenge amount profits taxed country reasonably possible ultimate resolution tax matters could materially affect shareholders equity liquidity andor cash flows company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions taxing authorities company accrues liabilities identified tax contingencies result tax positions taken could challenged tax authorities company believes tax reserves reflect probable table contents outcome identified tax contingencies reasonably possible ultimate resolution tax matters may materially greater less amount accrued company records valuation allowance reduce deferred tax assets amount likely realized company considered ongoing prudent feasible tax planning strategies assessing need valuation allowance event company determine would able realize additional portion net deferred tax assets adjustment valuation allowance would increase income period determination made likewise company subsequently determine would able realize additional portion remaining net deferred tax asset future adjustment deferred tax asset would charged income period determination made impairment intangible assets property intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled million december annual amortization expense next five years estimated approximately million per year based intangible assets recorded december value assets subject continuing scientific medical marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment many companys manufacturing sites operate capacity overall costs operating manufacturing sites significantly increased due consent decree compliance activities companys manufacturing cost base relatively fixed actions part management significantly reduce companys manufacturing infrastructure involve complex issues cases shifting products manufacturing plants take many years due construction revalidation registration requirements management continues review carrying value certain manufacturing assets indications impairment future events decisions may lead asset impairments andor related costs accounting pension postretirement benefit plans pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions company assesses pension postretirement benefit plan assumptions regular basis evaluating assumptions company considers many factors including evaluation discount rate expected rate return plan assets healthcare cost trend rate retirement age assumption companys historical assumptions compared actual results analysis current market conditions asset allocations see note retirement plans postretirement benefits item financial statements supplementary data k additional information discount rates used pension postretirement benefit plan calculations evaluated annually modified reflect prevailing market rate measurement date highquality fixed income debt instrument portfolio would provide future cash flows needed pay benefits included benefit obligations come due countries debt instruments thinly traded estimates based available market rates actuarial assumptions based upon managements best estimates judgment increase basis points discount rate assumption assumptions held constant would estimated million favorable impact net pension postretirement benefit cost increase basis points expected rate return assumption assumptions held constant would estimated million favorable impact net pension post retirement benefit cost table contents expected rates return pension postretirement benefit plans represent average rates return earned plan assets period benefits included benefit obligation paid developing expected rate return company determines expected returns major asset classes principally equities fixed income real estate return expectations asset classes based assumptions economic growth inflation supported long term historical data well companys actual experience return plan assets expected portfolio performance also reflects contribution active management appropriate unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based primarily calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns majority assets realized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees targeted investment portfolio companys us pension plan allocated percent equities percent fixed income investments percent real estate targeted investment portfolio companys us postretirement benefit plans allocated percent equities percent fixed income investments portfolios equity weightings consistent longterm nature plans benefit obligations nonus pension plans targeted investment portfolio varies based duration pension liabilities local governmental rules regulations substantially investments equities fixed income valued based quoted public market values investments real estate valued based periodic appraisals accounting legal regulatory matters management judgments estimates required accounting legal regulatory matters ongoing basis including insurance coverages company reviews status claims investigations legal proceedings ongoing basis time time company may settle otherwise resolve matters terms conditions management believes best interests company resolution claims investigations legal proceedings individually aggregate could material adverse effect companys results operations cash flows financial condition market risk disclosure company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk company subsidiaries countries sales outside us accounted approximately percent global sales virtually sales denominated currencies local country companys reported profits cash flows exposed changing exchange rates date management deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments companys international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provides level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact companys international operations widespread table contents addition point time companys international subsidiaries hold financial assets liabilities denominated currencies us dollars financial assets liabilities consist primarily shortterm third party intercompany receivables payables changes exchange rates affect translated value financial assets liabilities gains losses arise translation affect net income occasion company used derivatives hedge specific shortterm risk situations involving foreign currency exposures however derivative transactions material interest rate equity price risk financial assets exposed changes interest rates andor equity prices primarily cash equivalents shortterm investments debt equity securities held nonqualified trusts employee benefits assets totaled billion december cash equivalents shortterm investments percent decrease interest rates would decrease interest income approximately million securities held nonqualified trusts due longterm nature liabilities trust assets fund companys exposure market risk deemed low financial obligations exposed variability interest rates primarily shortterm borrowings company maintains investment portfolio excess amount borrowings accordingly company mitigated exposure changes interest rates relating financial obligations company longterm debt outstanding percent decrease interest rates would increase fair value debt approximately million however company expect refund debt disclosure notice cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time company may contain forwardlooking statements within meaning private securities litigation reform act forwardlooking statements relate strictly historical current facts based current expectations forecasts future events identify forwardlooking statements use words anticipate believe could estimate expect forecast project intend plan potential similar words terms particular forwardlooking statements include statements relating future actions ability access capital markets prospective products product approvals timing conditions regulatory approvals patent intellectual property protection future performance results current anticipated products sales efforts research development programs estimates rebates discounts returns expenses programs reduce expenses cost savings reductions work force outcome contingencies litigation investigations growth strategy financial results forwardlooking statements publications may turn wrong guarantees companys financial operational performance performance companys stock company assume obligation update forwardlooking statement many factors could cause actual results differ companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known although possible predict identify factors refer item risk factors report incorporate herein reference identification important factors respect risks uncertainties item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis financial condition results operations k table contents item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements report independent registered public accounting firm table contents scheringplough corporation subsidiaries statements consolidated operations ye ars en ded december ounts illions exc ept per share figures net sales cost sales selling general administrative research development expenseincome net special charges equity income cholesterol joint venture incomeloss income taxes income tax expense net incomeloss preferred stock dividends net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share dividends per common share accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows f ye ars en ded december amounts millions operating activities net incomeloss adjustments reconcile net incomeloss net cash provided byused operating activities payments us taxing authorities tax refunds us loss carryback special charges depreciation amortization changes assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities income taxes payable net cash provided used operating activities investing activities capital expenditures dispositions property equipment proceeds transfer license purchases investments reduction investments net net cash used investing activities financing activities cash dividends paid common shareholders cash dividends paid preferred shareholders proceeds preferred stock issuance net shortterm borrowings payments shortterm borrowings issuance longterm debt reductions longterm debt net net cash used provided financing activities effect exchange rates cash cash equivalents net decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash paid interest net amounts capitalized cash paid refunded income taxes see note accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets decembe r amounts illions except per share figures assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt us foreign state income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt deferred income taxes longterm liabilities total longterm liabilities commitments contingent liabilities note shareholders equity mandatory convertible preferred shares par value issued per share face value common shares authorized shares par value issued paidin capital retained earnings accumulated comprehensive income total less treasury shares cost total shareholders equity total liabilities shareholders equity accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity accu mulated mandatory total convertible compre share preferred common paidin retained treasury hensive holders shares shares capital earnings shares income equity amoun ts millio ns balance january comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investments available sale net tax total comprehensive loss cash dividends common shares stock incentive plans balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investments available sale net tax total comprehensive loss issuance preferred stock cash dividends common shares dividends preferred shares stock incentive plans balance december comprehensive income net income foreign currency translation minimum pension liability net tax total comprehensive income cash dividends common shares dividends preferred shares stock incentive plans balance december accompanying notes integral part consolidated financial statements table contents notes consolidated financial statements summary significant accounting policies overview scheringplough company discovers develops manufactures markets medical therapies treatments enhance human health company also markets leading consumer brands overthecounter otc foot care sun care markets operates global animal health business principles consolidation consolidated financial statements include scheringplough corporation subsidiaries company intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity generally accepted accounting principles requires management make estimates use assumptions affect certain reported amounts disclosures actual amounts may differ equity method accounting company accounts share activity merck scheringplough cholesterol joint venture partnership joint venture merck co inc merck using equity method accounting company significant influence joint ventures operating financial policies accordingly companys share earnings joint venture included consolidated net incomeloss revenue sales vytorin zetia recognized joint venture title risk loss passed customer equity income joint venture excludes profit arising transactions company joint venture time underlying profit realized joint venture transaction party company merck see note equity income cholesterol joint venture information regarding joint venture cash cash equivalents cash cash equivalents include operating cash highly liquid investments original maturities three months less shortterm investments shortterm investments carried fair value classified available sale investments consist time deposits certificates deposit commercial paper maturities less year inventories inventories valued lower cost market cost determined using lastin firstout lifo method substantial portion inventories located us cost inventories determined firstin firstout method fifo depreciation property equipment depreciation provided estimated useful lives properties generally use straightline method table contents notes consolidated financial statements continued useful lives property generally follows asset category year buildings building improvements equipment company reviews carrying value property equipment indications impairment accordance statement financial accounting standard sfas accounting impairment disposal longlived assets depreciation expense million million million respectively foreign currency translation net assets companys international subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included comprehensive income remaining international subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation account transactional exchange gains losses included income revenue recognition companys pharmaceutical products sold direct purchasers eg wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies well indirect purchasers market participants eg managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers company recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue company estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period estimates recorded prior periods reevaluated part process reliable estimates items made company defers recognition revenue earnings per common share diluted earnings per common share computed dividing income available common shareholders sum weighted average number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options impact table contents notes consolidated financial statements continued conversion mandatory convertible preferred shares excluded calculation since including securities earnings per share calculation would antidilutive diluted loss per common share excludes effect shares issuable deferred stock units exercise stock options impact conversion mandatory convertible preferred shares including securities earnings per share calculation would antidilutive would result lower loss per share diluted loss per common share excludes effect shares issuable deferred stock units exercise stock options including securities would antidilutive periods presented basic earningsloss per common share computed dividing incomeloss available common shareholders weighted average number common shares outstanding goodwill intangible assets sfas goodwill intangible assets requires intangible assets acquired either individually group assets initially recognized measured based fair value intangible finite life amortized useful life intangible indefinite life including goodwill amortized company evaluates goodwill impairment using fairvaluebased test goodwill determined impaired written estimated fair value companys goodwill primarily related animal health business income taxes deferred income taxes recognized future tax effects temporary differences financial income tax reporting basis companys assets liabilities based enacted tax laws rates accounting stockbased compensation december company accounted stockbased compensation arrangements using intrinsic value method stockbased employee compensation cost reflected net incomeloss companys deferred stock units performance plans stock options granted plans exercise price equal market value underlying common stock date grant december fasb issued sfas revised sharebased payment sfas r sfas r effective company january sfas r requires companies recognize compensation costs related sharebased transactions compensation based market performance companys shares determined fair value basis company adopt sfas r first quarter using modified prospective method modified prospective method requires company recognize compensation costs sharebased grants made january well unrecognized cost unvested awards date adoption upon adoption sfas r company recognize sharebased compensation costs service period earlier employees retirement eligibility date stated vesting period award grants issued retirement eligible employees prior adoption sfas r company recognize compensation costs stated vesting period acceleration unrecognized compensation costs upon retirement employee sfas r also amends sfas statement cash flows require excess tax benefits reflected operating cash flows reflected financing cash flows table contents notes consolidated financial statements continued addition company two compensation plans accounted sfas r liabilitybased plans ultimate cash payout liabilitybased plans based companys stock price performance compared stock price performance peer group change accounting required sfas r result cumulative effect million income january order recognize difference companys previously accrued liability reported accounting principles board apb opinion number accounting stock issued employees fair value liability plans future operating results impacted fluctuation fair value liability plans required remeasured reporting date following table reconciles net incomeloss available common shareholders basicdiluted earningsloss per common share reported pro forma net incomeloss available common shareholders basicdiluted earningsloss per common share company expensed grantdate fair value stock options deferred stock units permitted sfas accounting stockbased compensation dollars millions except per share data net incomeloss available common shareholders reported add back expense included reported net income deferred stock units net tax deduct pro forma expense stock options deferred stock units charged net incomeloss available common shareholders accordance sfas net tax pro forma net incomeloss available common shareholders using fair value method diluted earningsloss per common share diluted earningsloss per common share reported pro forma diluted earningsloss per common share using fair value method basic earningsloss per common share basic earningsloss per common share reported pro forma basic earningsloss per common share using fair value method weightedaverage fair value options granted respectively fair values estimated using blackscholes optionpricing model based following assumptions dividend yield volatility riskfree interest rate expected term options years impact recently issued accounting pronouncements november fasb issued sfas inventory costs sfas requires abnormal spoilage expensed period incurred opposed inventoried amortized income table contents notes consolidated financial statements continued inventory usage fixed production facility overhead costs allocated normal production level facility company implemented sfas fourth quarter implementation sfas material impact companys financial statements march fasb issued interpretation fin sfas accounting conditional asset retirement obligations clarify term conditional asset retirement obligations used sfas term refers legal obligation perform asset retirement activity timing andor method settlement conditional future event may may within control entity accordingly company required recognize liability fair value conditional asset retirement obligation fair value liability reasonably estimated interpretation effective later end fiscal year ending december retroactive application required company implemented fin fourth quarter implementation fin material impact companys financial statements special charges components special charges year ended december follows dollars million litigation charges employee termination costs asset impairment related charges litigation charges litigation reserves increased million resulting total reserve million massachusetts investigation well investigations disclosed awp investigations state litigation disclosed awp litigation note legal environmental regulatory matters litigation reserves increased million primarily result investigations companys sales marketing practices see note legal environmental regulatory matters additional information employee termination costs august company announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program retired december total cost program approximately million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants million amounts recognized relating program years ended december million million million respectively employee termination costs associated verp totaled million million million respectively table contents notes consolidated financial statements continued following summarizes activity accounts related employee termination costs employ ee termination costs dol lars millions special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december asset impairment charges asset impairment charges recognized accordance sfas goodwill intangible assets sfas accounting impairment disposal longlived assets year ended december company recognized asset impairment charges million related primarily consolidation companys us biotechnology organizations year ended december company recognized asset impairment charges million based discounted cash flows charges million related primarily shutdown small european research development facility year ended december company recognized asset impairment charges related following asset impairment charges totaling million recognized based discounted cash flow analysis related facilities equipment two companys manufacturing sites asset impairment charge million based discounted cash flows recognized related intangible asset licensed cancer therapy drug sold countries outside us impairment charge million related trade name companys highend sun care brand recognized based discounted cash flows equity income cholesterol joint venture may company merck co inc merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements table contents notes consolidated financial statements continued generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide company merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approved use us launched several international markets company utilizes equity method accounting recording share activity merck scheringplough cholesterol joint venture companys net sales include sales joint venture cholesterol joint venture agreements provide sharing operating income generated joint venture based upon percentages vary product sales level country us market company receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough partners generally share profits equally scheringploughs allocation joint venture income increased milestones recognized either partners share joint ventures income operations subject reduction partner fails perform specified minimum number physician details particular country partners agree annually minimum number physician details country partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details set annual basis reimbursed amount equal partners physician details multiplied contractual fixed fee scheringplough reports reimbursement part equity income cholesterol joint venture amount represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount reflective companys sales effort related joint venture companys sales force related costs associated joint venture generally estimated higher year ended december company recognized milestones million milestones related certain european approvals vytorin ezetimibesimvastatin company recognized milestone million related approval ezetimibesimvastatin mexico company recognized milestones million related certain european approvals zetia certain conditions specified joint venture agreements merck company could earn additional milestones totaling million costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directto consumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners table contents notes consolidated financial statements continued following information provides summary components companys equity income cholesterol joint venture year ended december dollars million scheringploughs share net incomeloss including milestones respectively reimbursement scheringplough physician details elimination intercompany profit net total equity income cholesterol joint venture equity income joint venture excludes profit arising transactions company joint venture time underlying profit realized joint venture transaction party company merck due virtual nature cholesterol joint venture company incurs substantial costs selling general administrative costs reflected equity income borne overall cost structure company costs reported respective line items statements consolidated operations cholesterol agreements provide jointly owned facilities products resulting joint venture manufactured facilities owned either company merck allergyasthma agreements provide joint development marketing partners oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck scheringplough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remains clinical development new phase iii clinical trials planned expenseincome net components expenseincome net follows ollars million interest cost incurred less amount capitalized construction interest expense interest income foreign exchange losses net total expenseincome net table contents notes consolidated financial statements continued income taxes components consolidated incomeloss income taxes years ended december follows dollars millions united states foreign total incomeloss income taxes income cholesterol joint venture included table based jurisdiction income earned components income tax expense years ended december follows fede ral sta te fore ign tot al ollars millions current deferred total current deferred total current deferred total companys tax provision year ended december includes us federal income tax benefit approximately million result irs notice issued august provisions notice resulted reduction previously accrued tax liability attributable american jobs creation act ajca repatriation also reduced us net operating loss nol carried forward subsequent years fourth quarter company made decision repatriate approximately billion provisions ajca maximum amount foreign earnings qualified reduced tax rate percent intended repatriation earnings resulted us federal tax liability approximately million state income tax liability approximately million recorded income tax expense company repatriated approximately billion accordance planned repatriation ajca company continue use repatriated funds qualified spending prior ajca companys intent permanently reinvest unremitted earnings international subsidiaries except amounts repatriated ajca company maintains intent permanently reinvest earnings international subsidiaries company provided deferred taxes approximately billion undistributed foreign earnings december determining tax liability would arise earnings remitted practicable table contents notes consolidated financial statements continued liability would depend number factors including amount earnings distributed whether us operations generating taxable profits losses fourth quarter due changes tax planning strategies triggered companys intent repatriate earnings ajca management longer able conclude likely would realize benefit net us deferred tax assets including benefit related us nols therefore general company established valuation allowance net us deferred tax asset december company continues maintain valuation allowance net us deferred tax asset december deferred income taxes provided temporary differences financial reporting basis tax basis companys assets liabilities companys deferred tax assets result principally recording certain items currently deductible tax purposes net operating loss tax credit carryforwards companys deferred tax liabilities principally result use accelerated depreciation tax purposes components companys deferred tax assets liabilities december follows dollars illions deferred tax assets net operating losses nols tax credit carryforwards postretirement employee benefits inventory related sales return reserves litigation accruals total deferred tax assets deferred tax liabilities depreciation inventory valuation total deferred tax liabilities deferred tax valuation allowance net deferred tax assets change valuation allowance primarily due increase us nol deferred taxes net operating losses carryforwards principally relate us nols research development rd tax credits us foreign tax credits federal alternative minimum tax amt credit carryforwards december company approximately billion us nols income tax purposes available offset future us taxable income us nols expire varying amounts unused december company approximately million rd tax credits carryforwards expire million foreign tax credit carryforwards expire million amt tax credit carryforwards indefinite life approximately million billion us nols generated respectively eligible carryback benefits provision us tax law accordance provision company able table contents notes consolidated financial statements continued recoup previous us taxes paid resulted income tax benefits million million respectively difference income taxes based us statutory tax rate companys income tax expense years ending december due following dollars million income tax expensebenefit us statutory rate increasedecrease taxes resulting lower rates jurisdictions net federal benefit tax repatriated foreign earnings act net credits us nols tax benefit recorded provision valuation allowance net us deferred tax assets nondeductible litigation reserves reserves tax litigation research tax credit state income tax permanent differences net income tax effective tax rate lower tax rates jurisdictions net primarily attributable companys manufacturing subsidiaries puerto rico singapore ireland operate various incentive tax grants begin expire overall income tax expense primarily relates foreign taxes include benefit related us nols net consolidated income tax paymentsrefunds exclusive payments related tax examinations litigation discussed million million million respectively january internal revenue service irs completed examination companys federal income tax returns company made cash payment third quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charges payment fully satisfied liability associated tax examination consistent previously recorded reserves irs currently examining companys federal income tax returns companys potential tax exposures result varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property although companys cross border arrangements affiliates based upon internationally accepted standards tax authorities various jurisdictions may disagree subsequently challenge amount profits taxed country reasonably possible ultimate resolution tax matters could materially affect shareholders equity liquidity andor cash flows company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions taxing authorities company accrues liabilities identified tax contingencies result tax positions taken could challenged tax authorities company believes tax reserves reflect table contents notes consolidated financial statements continued probable outcome identified tax contingencies reasonably possible ultimate resolution tax matters may materially greater less amount accrued october irs auditors asserted two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september company made payments irs amount million income tax million interest company filed refund claims tax interest irs december following irss denial companys claims refund company filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase companys tax reserves adequate cover mentioned payments retirement plans postretirement benefits plan descriptions company defined benefit pension plans covering eligible employees us certain foreign countries us plan benefits normal retirement primarily based upon participants average final earnings years service social security income modified early retirement death disability benefits also available plan benefits become fully vested five years service plan provides continued accrual credited service employees opt postpone retirement remain employed company reaching normal retirement age nonus pension plans offer benefits competitive local market conditions addition company provides postretirement medical life insurance benefits eligible us retirees dependents postretirement benefit plans measurement date majority plans liabilities december net pension postretirement benefit costs totaled million compared million million actuarial assumptions consolidated weighted average assumptions used determine benefit obligations december ot r pos retirement retirement plans benefits discount rate rate increase future compensation na na assumptions used develop benefit obligations yearend consolidated weighted average assumptions used determine net benefit costs years ended december ot pos treti rem ent retirement plans benefits discount rate longterm expected rate return plan assets rate increase future compensation na na na table contents notes consolidated financial statements continued assumptions used determine net periodic benefit costs year established end previous year assumptions used determine benefit obligations established yearend net periodic benefit costs actuarial present value benefit obligations based actuarial assumptions determined annually based evaluation longterm trends well market conditions may impact cost providing retirement benefits longterm expected rates return plan assets derived return assumptions determined major asset classes equities fixed income real estate proportional basis return expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weighted average assumed healthcare cost trend rate used postretirement measurement purposes percent trending percent one percent increase assumed healthcare cost trend rate would increase combined postretirement service interest cost million post retirement benefit obligation million one percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assumed based annual rates retirement experienced company components net periodic benefit costs components net pension postretirement benefits expense follows ot p os treti rem ent retirement plans benefits ollars millio ns service cost interest cost expected return plan assets amortization net termination benefits curtailment settlement net pension postretirement benefits expense termination benefits curtailment settlement costs primarily relate matters discussed note special charges table contents notes consolidated financial statements continued benefit obligations funded status components changes benefit obligations follows ot postretirement retirement plans benefits ollars illions benefit obligations beginning year service cost interest cost participant contributions effects exchange rate changes benefits paid acquisitions plan transfers actuarial lossesgains including assumption change plan amendments termination benefits curtailment benefit obligations end year benefit obligations overfunded plans benefit obligations underfunded plans termination benefits curtailment costs primarily relate matters discussed note special charges components changes plan assets follows ot p ost retirement retirement plans benefits llars illions fair value plan assets primarily stocks bonds beginning year actual gain loss plan assets contributions acquisitions plan transfers effects exchange rate changes benefits paid fair value plan assets end year plan assets overfunded plans plan assets underfunded plans addition plan assets indicated december securities investments million million respectively held nonqualified trust designated provide pension benefits certain underfunded plans december accumulated benefit obligations abo retirement plans million million respectively aggregated accumulated benefit obligations table contents notes consolidated financial statements continued fair values plan assets retirement plans accumulated benefit obligations excess plan assets million million respectively december million million respectively december accordance fasb staff position accounting disclosure requirements related medicare prescription drug improvement modernization act medicare act company began accounting effect federal subsidy medicare act third quarter result companys accumulated postretirement benefit obligation reduced million companys net postretirement benefits expense reduced million reduction postretirement benefits expense consists reductions service cost interest cost net amortization million million million respectively following reconciliation funded status plans net assetliability ot postretirement retirement plans benefits ollars illions benefit obligations excess plan assets post measurement date contributions unrecognized prior service costs unrecognized net actuarial loss net assetliability end year unrecognized actuarial gains losses primarily represent cumulative difference actuarial assumptions actual returns plan assets changes discount rates plans experience december company unrecognized net actuarial loss million retirement plans million postretirement benefit plans total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees components net assetliability recorded consolidated balance sheet follows oth er postretirement retirement plans benefits dollars millions prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net assetliability end year december companys additional minimum pension liability million million respectively primarily related domestic retirement plans resulted adjustment accumulated comprehensive incomeloss net tax million million respectively table contents notes consolidated financial statements continued plan assets fair value asset allocation consolidated retirement plans december target allocation follows pe rcen tage plan assets target december allocation asset category equity securities debt securities real estate total asset allocation postretirement benefit trusts december target allocation follows pe rcen tage plan assets target december allocation asset category equity securities debt securities total companys investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns consistent acceptable level overall portfolio market value risk assets periodically rebalanced back target allocations estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid ot retirement postretirement plans benefits dollars millions years expected benefit payments reduced expected subsidy payments medicare act million million million million million million respectively companys practice fund qualified pension plans least sufficient amounts meet minimum requirements set forth applicable laws table contents notes consolidated financial statements continued company expects contribute approximately million retirement plans including million us retirement plan contribution us may change based outcome pending funding reform legislation defined contribution plans company defined contribution profitsharing plan covering substantially fulltime domestic employees completed one year service annual contribution determined formula based companys income shareholders equity participants compensation profit sharing contribution determined formula described company longer makes contributions plan beginning company makes contributions existing defined contribution savings plan equal three percent eligible employee earnings plus matching two percent eligible employee earnings based employee contributions plan total company contributions plan million million respectively earnings per common share following table reconciles components basic diluted earningsloss per share computations dol lars sha res millio ns eps numerator net incomeloss less preferred stock dividends net incomeloss available common shareholders eps denominator average shares outstanding basic eps dilutive effect options deferred stock units average shares outstanding diluted eps equivalent common shares issuable companys stock incentive plans excluded computation diluted eps effect would antidilutive million million million respectively years ended december respectively also years ended december million million common shares respectively obtainable upon conversion companys percent mandatory convertible preferred stock excluded computation diluted earnings per share effect would antidilutive comprehensive incomeloss components accumulated comprehensive incomeloss december dollars illions foreign currency translation adjustment minimum pension liability net tax unrealized gain investments available sale net tax total table contents notes consolidated financial statements continued gross unrealized pretax gains investments million respectively unrealized losses immaterial inventories inventories consisted following december dollars illions finished products goods process raw materials supplies total inventories inventories valued lastin firstout basis comprised approximately percent total inventories december estimated replacement cost total inventories december million million respectively intangible assets components intangible assets net follows december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net doll ars n million patents licenses trademarks total intangible assets included pension assets million million respectively patents licenses trademarks amortized straightline method respective useful lives residual value intangible assets estimated zero company recorded million base technology intangibles related acquisition neogenesis assets amount amortized five years company restructured integrilin copromotion agreement millennium pharmaceuticals inc millennium result million included intangible assets amortized approximately nine years included intangible assets approximately million related license copromotion agreements bayer amounts amortized effective useful lives agreements ranging seven years see note product licenses acquisitions additional information transactions net carrying amount patents licenses reduced approximately million result bristolmyers squibbs reacquisition co promotion rights tequin us amortization expense related intangible assets million million million respectively intangible assets reviewed determine table contents notes consolidated financial statements continued recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review product licenses acquisitions february company acquired assets neogenesis pharmaceuticals approximately million million recorded intangible asset related base technology neogenesis applies novel screening chemistry technologies discover new drug candidates august company announced exercised right develop commercialize centocor inc centocor golimumab fully human monoclonal antibody developed therapy treatment rheumatoid arthritis immunemediated inflammatory diseases pursuant exercise company receives exclusive worldwide marketing rights golimumab excluding us japan china including hong kong taiwan indonesia exchange rights agreement company made upfront payment amount million centocor tax benefit million payment expensed reported research development year ended december statements consolidated operations company sharing development costs centocor effective september company restructured integrilin copromotion agreement millennium terms restructured agreement company acquired exclusive us development commercialization rights integrilin exchange upfront payment million royalties integrilin sales company agreed pay minimum royalties million per year millennium company also purchased existing integrilin inventory millennium million upfront payment capitalized included intangible assets company entered collaboration license agreement toyama chemical co ltd toyama terms agreement company acquired exclusive worldwide rights excluding japan korea china develop use sell garenoxacin human veterinary uses excluding topical ophthalmic applications garenoxacin toyamas quinolone antibacterial agent currently regulatory review us connection execution agreement company incurred charge second quarter upfront fee million toyama amount expensed reported research development year ended december statements consolidated operations company entered strategic agreement bayer intended enhance companys pharmaceutical resources terms agreement company exclusive rights us puerto rico market sell distribute avelox cipro antibiotics uses excluding certain topical formulations administration eye ear company pays bayer royalties generally excess percent products based sales agreement company also undertook bayers us commercialization activities erectile dysfunction medicine levitra bayers co promotion agreement glaxosmithkline plc japanese market bayer comarket companys cholesterolabsorption inhibitor zetia approved company received recorded deferred revenue million related sale zetia copromotion rights bayer deferred revenue begin recognized upon regulatory approval japan zetia currently regulatory review japan certain circumstances zetia receive regulatorymarketing approval japan certain date amount required repaid bayer agreement bayer potentially restricts company marketing products us would compete products agreement result company expects table contents notes consolidated financial statements continued sublicense rights garenoxacin quinolone antibacterial agent company licensed toyama shortterm borrowings longterm debt commitments short longterm borrowings general shortterm borrowings consist bank loans commercial paper issued us shortterm borrowings december totaled billion billion respectively included shortterm borrowings commercial paper outstanding december million billion respectively weighted average interest rate shortterm borrowings december percent percent respectively november company issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due interest payable semiannually net proceeds offering billion upon issuance notes rated moodys investors service inc moodys standard poors rating services sp interest rates payable notes subject adjustment follows rating assigned particular series notes either moodys sp changes rating set forth interest rate payable series notes initial interest rate percent notes due percent notes due plus additional interest rate set forth moodys sp additional interest rate moody rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade either moodys sp respectively notes subsequently rated baa moodys bbb sp july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december therefore effective december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent december notes rated baa moodys sp notes redeemable whole part companys option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes credit facilities company revolving credit facility syndicate major financial institutions march company negotiated increase commitment facility billion billion changes basic terms preexisting credit facility concurrently table contents notes consolidated financial statements continued increase commitments facility company terminated early separate million line credit would matured may outstanding balance facility time terminated existing billion credit facility matures may requires company maintain total debt capital ratio percent credit line available general corporate purposes management considers facility support companys commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december million drawn facility whollyowned international subsidiary fund ajca repatriations addition aforementioned credit facility company entered million credit facility fourth quarter drawn december credit facility utilized whollyowned international subsidiary fund repatriations ajca credit facility requires company maintain total debt total capital ratio percent borrowings payable later november funds borrowed facility subsequently repaid may reborrowed credit facility borrowings classified shortterm borrowings company intends repay amounts next twelve months addition companys international subsidiaries approximately million available unused lines credit various financial institutions december commitments total rent expense amounted million million million future annual minimum rental commitments noncancelable operating leases december follows million million million million million aggregate minimum lease obligations million due thereafter december capital lease obligations million million included current portion longterm debt longterm debt respectively december company commitments totaling million related capital expenditures made financial instruments sfas derivative instruments financial hedging activities amended requires derivatives recorded balance sheet fair value accounting standard also provides effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized income occur risks policy objectives company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes time time company hedge selective foreign currency risks derivatives currently management deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments companys international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory table contents notes consolidated financial statements continued related payables rate inventory turnover provide natural level protection adverse changes exchange rates furthermore risk adverse exchange rate change somewhat mitigated fact companys international operations widespread limited basis company hedge selective foreign currency contract exposures mitigate exchange rate risks company mitigates credit risk derivative instruments dealing counterparties considered financially sound accordingly company anticipate loss nonperformance company enter derivative instruments generate trading profits table presents carrying values estimated fair values certain companys financial instruments december estimated fair values determined based market prices available dealer quotes carrying values financial instruments including cash cash equivalents approximated estimated fair values december carrying estimated carrying estimated value fair value value fair value dollars millions assets shortterm investments longterm investments liabilities shortterm borrowings current portion longterm debt longterm debt longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held nonqualified trusts fund long term employee benefit obligations included liabilities consolidated balance sheets assets used fund related liabilities interest rate swap contract prior march company interest rate swap arrangement effect counterparty bank arrangement utilized two longterm interest rate swap contracts one foreignbased subsidiary company bank us subsidiary company bank two contracts equal offsetting terms covered master netting arrangement contract involving foreignbased subsidiary permitted subsidiary prepay portion future obligation bank contract involving us subsidiary permitted bank prepay portion future obligation us subsidiary prepayments totaling billion made contracts december terms swap contracts amended called phased termination swaps based agreed repayment schedule begin later march termination would require company counterparty repay prepayments pursuant agreed repayment schedule company option allowed accelerate termination arrangement associated scheduled repayments nominal fee february companys foreignbased subsidiary us subsidiary gave notice counterparty intent terminate arrangement march company terminated swap agreements associated repayments made respective obligors table contents notes consolidated financial statements continued termination arrangement material impact companys statement consolidated operations shareholders equity company authorized shares preferred stock consists preferred shares designated series junior participating preferred stock preferred shares designated percent mandatory convertible preferred stock preferred shares whose designations yet determined percent mandatory convertible preferred stock shelf registration august company issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds company billion deducting commissions discounts underwriting expenses preferred stock automatically convert common shares company depending average closing price companys common shares period immediately preceding mandatory conversion date september defined prospectus preferred shareholders may elect convert time prior september minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price companys common shares exceeds least trading days within period consecutive trading days company may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares preferred share preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent company legally permitted pay dividends board directors declares dividend payable company pay dividends dividend payment date dividend payment dates march june september december first dividend paid december december company ability issue million principal amount securities currently effective securities exchange commission sec shelf registration treasury stock summary treasury share transactions years ended december follows hares milli ons share balance january shares issued stock incentive plans share balance december preferred share purchase rights company preferred share purchase rights outstanding attached presently trade companys common shares exercisable rights become exercisable person group acquires percent companys common stock announces tender offer completed would result ownership person group percent companys common stock person group acquire percent companys outstanding common stock merger business combination transaction right table contents notes consolidated financial statements continued entitle holder acquirer purchase common shares scheringplough market value twice exercise price right exercise price rights following acquisition person group beneficial ownership percent less percent companys common stock board directors may call exchange rights rights owned acquirer whole part exchange ratio one common share one twohundredth share series junior participating preferred stock per right also prior acquisition person group beneficial ownership percent companys common stock rights redeemable per right option board directors rights expire july unless earlier redeemed exchanged board directors also authorized reduce percent thresholds referred less greater sum percent largest percentage outstanding shares common stock known company beneficially owned person group affiliated associated persons ii percent except following acquisition person group beneficial ownership percent companys common stock reduction may adversely affect interests holders rights stock incentive plans terms companys stock incentive plan approved companys shareholders million companys common shares may granted stock options awarded deferred stock units officers certain employees company december december million options deferred stock units remain available future year grants stock incentive plan option exercise prices equal market price common shares grant dates options expire later years date grant options granted generally three year vesting term granted prior generally oneyear vesting term option grants vest longer periods ranging three nine years deferred stock units payable equivalent number common shares shares distributable single installment three five equal annual installments generally commencing three years date award following table summarizes stock option activity past three years current prior plans incentive plans approved companys shareholders weighted weighted weighted number average number average number average exercise exercise exercise options price options price options price num ber options illions outstanding january granted exercised canceled expired outstanding december exercisable december table contents notes consolidated financial statements continued summarized information stock options outstanding exercisable december follows standing weighted average weighted weighted number remaining average exercisable average term exercise number exercise exercise price range options years price options price number options mi llions company awarded deferred stock units totaling million units million units million units respectively weighted average fair values deferred stock units granted respectively insurance coverage company maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly result recent external events availability insurance become restrictive management considers impact changes continually assesses best way provide insurance needs future company selfinsures substantial proportion risk relates products liability segment information company three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent companys current management reporting structure prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products consumer health care segment develops manufactures markets overthecounter foot care sun care products primarily us animal health segment discovers develops manufactures markets animal health products net sales segment ye ar en ded decem ber dollars millions prescription pharmaceuticals consumer health care animal health consolidated net sales table contents notes consolidated financial statements continued profit segment ear e nded ecem ber dollars millions prescription pharmaceuticals consumer health care animal health corporate consolidated profitloss tax corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve million representing companys current estimate resolve massachusetts investigation well investigations disclosed awp investigations state litigation disclosed awp litigation note legal environmental regulatory matters estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs well million asset impairment charges million closure costs primarily related exit small european research development facility estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs million provision increase litigation reserves million asset impairment charges estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million table contents notes consolidated financial statements continued net sales major product dollars n millions prescription pharmaceuticals remicade pegintron nasonex clarinex aerius temodar claritin rx rebetol integrilin intron avelox subutex caelyx cipro elocon pharmaceutical consumer health care otc includes otc claritin sales respectively foot care sun care animal health consolidated net sales net sales geographic area dollars millions united states europe canada pacific area asia latin america consolidated net sales company subsidiaries countries outside us single foreign country except france italy japan accounted percent consolidated net sales table contents notes consolidated financial statements continued past three years net sales presented geographic area companys customers located consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions total international net sales france japan italy net sales customer consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars n millions mckesson corporation single customer except mckesson corporation major pharmaceutical health care products distributor accounted percent consolidated net sales past three years longlived assets geographic location dollars millions united states singapore ireland puerto rico total longlived assets shown geographic location primarily property supplemental sales information sales products comprising percent companys us international sales year ended december follows amo unt perce ntage dollars millions us nasonex otc claritin international remicade pegintron table contents notes consolidated financial statements continued scheringploughs net sales include sales vytorin zetia marketed partnership merck company accounts joint venture equity method accounting see note equity income cholesterol joint venture company disaggregate assets segment basis internal management reporting therefore information presented consent decree may company agreed fda entry consent decree resolve issues related compliance current good manufacturing practices cgmp certain companys facilities new jersey puerto rico consent decree decree summary decree required company make payments totaling million two equal installments million paid addition decree required company complete revalidation programs manufacturing processes used produce bulk active pharmaceutical ingredients finished drug products covered facilities well implement comprehensive cgmp work plan facility decree required foregoing completed accordance strict schedules provided possible imposition additional payments event company adhere approved schedules final completion work made subject certification independent experts whose certifications turn made subject fda acceptance september company completed revalidation third party certification bulk active pharmaceutical ingredients december company completed revalidation third party certification finished drug products company also completed significant steps cgmp work plan december requirements completed accordance schedules required decree terms decree provided fda notified company significant violation fda law regulations decree five year period since decrees entry may may company may petition court decree dissolved fda oppose companys petition although company reported fda completed revalidation programs cgmp work plan third party certification work plan still pending possible third party expert may certify completion work plan significant step fda may disagree experts certification event possible fda may assess additional payments permitted decree described detail general cgmp work plan contained significant steps whose timely satisfactory completion subject payments thousand per business day deadline missed payments may exceed million million years payments subject overall cap million company would expense additional payments assessed decree incurred legal environmental regulatory matters background company involved various claims investigations legal proceedings company records liability contingencies probable liability incurred amount reasonably estimated company adjusts liabilities contingencies reflect current best estimate probable loss minimum liability case may best estimate determinable company records minimum amount within probable range table contents notes consolidated financial statements continued liability expected insurance recoveries considered determining amounts recorded liabilities environmentalrelated matters company believes loss contingency reasonably possible rather probable amount loss estimated liability recorded however liability reasonably possible disclosure loss contingency made company reviews status claims investigations legal proceedings ongoing basis including related insurance coverages time time company may settle otherwise resolve matters terms conditions management believes best interests company resolution claims investigations legal proceedings individually aggregate could material adverse effect companys results operations cash flows financial condition resolution including settlements matters types set forth remainder note particular investigations frequently involve fines penalties amount would material results operations cash flows financial condition resolution matters may also involve injunctive administrative remedies would adversely impact business exclusion government reimbursement programs turn would material adverse impact business future financial condition cash flows results operations assurances company prevail matters discussed remainder note settlements reached acceptable terms including scope release provided absence injunctive administrative remedies would adversely impact business exclusion government reimbursement programs amounts exceed amounts reserved even acceptable settlement reached assurance investigations litigations commenced raising similar issues potentially exposing company additional material liabilities outcome matters discussed investigations could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs total liabilities reserved reflect estimate case investigations current estimate liability final settlement adjudication matters could possibly less could materially exceed liabilities recorded financial statements could material adverse impact companys financial condition cash flows operations company predict timing resolution matters outcomes except matters discussed remainder note recorded liabilities contingencies december related expenses incurred year ended december material opinion management based advice legal counsel ultimate outcome matters except matters discussed remainder note material impact companys results operations cash flows financial condition patent matters dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages investigations massachusetts investigation us attorneys office district massachusetts investigating broad range companys sales marketing clinical trial practices programs along warrick pharmaceuticals warrick companys generic subsidiary investigation focused following alleged practices providing remuneration managed care table contents notes consolidated financial statements continued organizations physicians others induce purchase schering pharmaceutical products offlabel marketing drugs submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program company cooperating investigation outcome investigation could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company recorded liability million related investigation well investigations described awp investigations state litigation described awp litigation company able reach settlement current estimate resolution matter could material adverse impact companys results operations beyond reflected date company able reach settlement current estimate cash flows financial condition andor business awp investigations company continues respond existing new investigations department health human services department justice several states industry company practices regarding average wholesale price awp investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain government drug reimbursements based awp company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates pricing matters awp litigation company continues respond existing new litigation certain states private payors industry company practices regarding average wholesale price awp litigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following companys announcement fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed company certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege company failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege company failed disclose alleged depth severity table contents notes consolidated financial statements continued manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares company stock may february complaint seeks compensatory damages behalf class court certified shareholder class october discovery ongoing shareholder derivative actions two lawsuits filed us district court district new jersey company certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints allege failure disclose material information breach fiduciary duty directors relating fda inspections investigations companys pricing practices sales marketing clinical trials practices lawsuits shareholder derivative actions purport assert claims behalf company two shareholder derivative actions pending us district court district new jersey consolidated one action august early stages product liability company previously disclosed defendant putative class action lawsuits involving alleged claims personal injuries arising plaintiffs ingestion phenylpropanolaminecontaining coughcold remedies ppa products class action lawsuits plaintiffs asserted claims personal injuries arising use laxative products sought refund purchase price laxatives purchased lawsuits dismissed resolved amounts paid resolve matters immaterial class action lawsuits currently exist concerning ppa claims individual lawsuits involving ppa products still pending company deems pending lawsuits immaterial aggregate company also previously disclosed defendant individual lawsuits relating recalled albuterol vanceril vancenase inhalers lawsuits dismissed resolved amounts paid resolve lawsuits immaterial erisa litigation march company served putative class action complaint filed us district court new jersey alleging company retired chairman ceo president richard jay kogan companys employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation kdur scheringploughs longacting potassium chloride product supplement used cardiac patients following commencement ftc administrative proceeding described alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages discovery ongoing antitrust matters kdur scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle related generic versions kdur lederle upsher smith filed abbreviated new drug applications andas april ftc started administrative proceeding scheringplough upshersmith lederle alleging anticompetitive effects settlements administrative law judge issued decision patent litigation settlements complied law respects dismissed claims company ftc staff appealed decision full commission full commission reversed decision table contents notes consolidated financial statements continued administrative law judge ruling settlements violate antitrust laws full commission issued cease desist order imposing various injunctive restraints federal court appeals set aside commission ruling vacated cease desist order august ftc filed petition seeking hearing us supreme court pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania company entered fiveyear corporate integrity agreement cia disclosed note consent decree company subject obligations consent decree fda failure comply obligations cia consent decree result financial penalties matters biopharma contract dispute biopharma srl filed claim civil court rome july docket th chamber certain scheringplough subsidiaries complaint alleges company fulfill duties distribution supply agreements biopharma scheringplough subsidiary distribution scheringplough generic products manufactured biopharma hospitals pharmacists france tax matters october irs auditors asserted two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september company made payments irs amount million income tax million interest company filed refund claims tax interest irs december following irss denial companys claims refund company filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase companys tax reserves adequate cover mentioned payments environmental company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law company alleged potentially responsible party prp company believes remote time material liability relation sites company estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps company records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries company december related consolidated statements operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states effectiveness companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion managements assessment effectiveness companys internal control financial reporting unqualified opinion effectiveness companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries quarterly data unaudited three mo nths e nd ed march june september december llars illions ex cept per hare figur es net sales cost sales gross profit selling general administrative research development expenseincome net special charges equity incomeloss cholesterol joint venture incomeloss income taxes income tax expensebenefit net incomeloss dividends preferred shares net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions see note special charges consolidated financial statements additional information relating special charges companys common shares listed principally traded new york stock exchange approximate number holders record common shares january table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated companys disclosure controls procedures end period covered k concluded companys disclosure controls procedures effective also concluded changes companys internal control financial reporting occurred companys recent fiscal quarter materially affected reasonably likely materially affect companys internal control financial reporting part changing business environment company operates company replacing upgrading number information systems process ongoing several years connection changes part companys management internal control financial reporting disclosure controls procedures management concluded new systems least effective respect controls prior systems examples changes information systems occurred replacement companys order entry accounts receivable information systems within us prescription pharmaceutical business medicaid management system managements report internal control financial reporting management scheringplough corporation responsible establishing maintaining adequate internal control financial reporting schering ploughs internal control system designed provide reasonable assurance companys management board directors regarding preparation fair presentation published financial statements internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assessed effectiveness companys internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based assessment management believes december companys internal control financial reporting effective scheringploughs independent auditors deloitte touche llp issued attestation report managements assessment companys internal control financial reporting report follows table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited managements assessment included accompanying managements report internal control financial reporting schering plough corporation subsidiaries company maintained effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment company maintained effective internal control financial reporting december fairly stated material respects based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission table contents also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant information concerning directors nominees directors incorporated reference proposal one election directors companys proxy statement annual meeting shareholders may information concerning executive officers included part filing caption executive officers registrant information concerning audit committee financial expert incorporated reference audit committee report companys proxy statement annual meeting shareholders may information concerning standards global business practices incorporated reference corporate governance materials companys proxy statement annual meeting shareholders may item executive compensation executive compensation incorporated reference executive compensation companys proxy statement annual meeting shareholders may item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management incorporated reference stock ownership companys proxy statement annual meeting shareholders may equity compensation plan information following information relates plans equity securities company may issued employees directors company plans equity securities may issued nonemployees except stock incentive plan predecessor plans certain stock options may transferable family members employeeoptionee related trusts table contents column co lumn b c olumn c numb er securities remaining available number securities future issuance issued weightedaverage equity upon exercise exercise price compensation outstanding outstanding plans excluding options warrants options securities reflected plan category rights warrants rights column equity compensat ion plans approved security holders stock incentive plan predecessor plans equity compensation plans approved security holders directors stock award plan na na scheringplough ireland approved profit sharing scheme na na nonplan inducement awards approved security holders restricted shares na total plan provides annual grant shares common stock nonemployee director directors may defer awards stock units pay shares common stock deferral period ends plan permits eligible employees work scheringploughs irish subsidiaries enjoy tax advantages christmas bonus percent percent pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts euro may deferred year employee employees may sell withdraw shares allocated accounts two three years represents restricted shares awarded pursuant restricted shares agreements outside equity compensation plan adopted company mr hassan awarded restricted shares upon commencement employment april ms cox awarded restricted shares upon commencement employment may awards restricted shares vest upon third anniversary award date nonplan awards authorized compensation committee board approved stockholders company item certain relationships related transactions information concerning certain relationships related transactions incorporated reference certain transactions companys proxy statement annual meeting shareholders may item principal accountant fees services information concerning principal accountant fees services incorporated reference proposal two ratify designation deloitte touche llp audit scheringploughs books accounts companys proxy statement annual meeting shareholders may table contents part iv item exhibits financial statement schedules following documents filed part report financial statements financial statements set forth item k financial statement schedules merckscheringplough cholesterol partnership combined financial statements index pa ge combined statements net sales contractual expenses years ended december unaudited combined balance sheets december combined statements cash flows years ended december unaudited combined statements partners capital years ended december unaudited notes combined financial statements years ended december unaudited independent auditors report schedule ii valuation qualifying accounts schedules listed omitted applicable required table contents index exhibits unless otherwise indicated exhibits part commission file number exhibit number description location restated certificate incorpora tion incorporated reference exh ibit companys q period ended september b amended restated bylaws incorporated reference exhibit companys k filed june rights agreement company bank new incorporated reference exhibit companys york dated june filed june b form participation rights agreement company incorporated reference exhibit companys chase manhattan bank national association registration statement form amendment filed trustee december file ci indenture dated november company incorporated reference exhibit companys k bank new york trustee filed november cii first supplemental indenture including form note dated incorporated reference exhibit companys k november filed november ciii second supplemental indenture including form note incorporated reference exhibit companys k dated november filed november civ global senior note due incorporated reference exhibit civ companys k year ended december cv global senior note due incorporated reference exhibit cv companys k year ended december executive incentive plan amended restated incorporated reference exhibit ai october companys k year ended december bi stock incentive plan amended incorporated reference exhibit companys k year ended december bii stock incentive plan amended december incorporated reference exhibit companys k year ended december biii amendment stock incentive plan effective incorporated reference exhibit b companys february k year ended december table contents exhibit number description location ci stock incentive plan incorporated reference ex hibit companys q period ended september cii amendment stock incentive plan effective incorporated reference exhibit february companys q period ended march ciii amendment stock incentive plan effective incorporated reference exhibit c february companys k year ended december stock incentive plan amended february incorporated reference exhibit companys k year ended december ei employment agreement dated april incorporated reference exhibit companys fred hassan company k filed april eii employment agreement dated may incorporated reference exhibit companys k carrie cox company filed may eiii letter agreement dated november robert incorporated reference exhibit eiii bertolini company companys k year ended december eiv employment agreement effective upon change control incorporated reference exhibit eiv dated november robert bertolini companys k year ended december scheringplough corporation ev letter agreement dated march thomas j incorporated reference exhibit companys q sabatino jr company period ended march evi form employment agreement effective upon change incorporated reference exhibit evi control company certain executives new companys k year ended december agreements beginning june evii form employment agreement company incorporated reference exhibit eiv executive officers effective upon change control companys k year ended december evii form amendment employment agreement incorporated reference exhibit company executive officers effective upon change companys q period ended september control evii forms amendment employment agreement incorporated reference exhibits eiia b company executive officers effective upon change companys k year ended december control effective january table contents exhibit number description location evii form employment agreement company incorporated reference ex hibit eiic executive officers effective upon change control companys k year ended december incorporating prior amendments january new agreements effective beginning january exi severance benefit plan amended restated effective incorporated reference exhibit exi december amendments april companys q period ended march exii savings advantage plan amended restated attached january fi amended restated directors deferred compensation plan incorporated reference exhibit b amended october trust related thereto companys q period ended september fii amended restated defined contribution trust incorporated reference exhibit aii companys k year ended december gi supplemental executive retirement plan amended incorporated reference exhibit e restated february companys q period ended march gii amendment supplemental executive retirement plan incorporated reference exhibit effective november companys q period ended september giii second amendment supplemental executive retirement incorporated reference exhibit g plan effective october companys k year ended december giv amended restated serp rabbi trust agreement incorporated reference exhibit g companys k year ended december h directors stock award plan amended restated incorporated reference exhibit h february companys k year ended december deferred compensation plan amended restated incorporated reference exhibit october companys k year ended december ki form split dollar agreement related collateral incorporated reference exhibit l assignment company executive companys k year ended december officers kii form amendment split dollar agreement related incorporated reference exhibit g collateral assignment company executive companys q period ended march officers table contents exhibit number description location l retirement benefits equalization plan amended restated attached january operations management team incentive plan incorporated reference exhibit companys k year ended december n cash longterm incentive plan amended restated incorporated reference exhibit n companys effective january k year ended december longterm performance share unit incentive plan amended incorporated reference exhibit companys restated effective january k year ended december p transformational performance contingent shares program incorporated reference exhibit p companys k year ended december q cholesterol governance agreement dated may incorporated reference exhibit companys k among company merck co inc dated october parties signatory thereto r first amendment cholesterol governance agreement incorporated reference exhibit companys k dated december among company filed october merck co inc parties signatory thereto master agreement dated december incorporated reference exhibit companys k among company merck co inc parties filed october signatory thereto letter agreement dated april relating consent incorporated reference exhibit companys q decree period ended march u distribution agreement company centocor incorporated reference exhibit u companys inc dated april amended k year ended december filed may v amended restated directors deferred stock equivalency incorporated reference exhibit companys program q period ended september w summary director compensation incorporated reference exhibit w companys k year ended december computation ratio earnings fixed charges attached table contents exhibit number description location standards global business pr actices covers employees incorporated reference exh ibit companys k including senior financial officers filed september subsidiaries registrant attached consent independent registered public accounting firm attached independent auditors consent attached power attorney attached sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer compensatory plan contract arrangement certain portions exhibit omitted pursuant request confidential treatment nonpublic information filed separately securities exchange commission pursuant rule b securities exchange act amended copies